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Glycaemic control (GC) in the intensive care unit is clinically contentious. Hyperglycaemia, 
hypoglycaemia, and glycaemic variability are increased with many GC protocols, and, critically, all 
associated with increased morbidity and mortality. While some studies and physiological evidence 
suggests GC should benefit hyperglycaemic patients, others show no or negative effects and increased 
incidence of hypoglycaemia. Interpretation of results is made more difficult by differences in the 
measurement and reporting of glycaemic control, blood glucose (BG) levels and variability in patients. 
In addition, target ranges for glycaemic control are not universally accepted, and higher targets are often 
used out of fear of hypoglycaemia, rather than their relationship to a clinical outcome.  
 
The issues of hyperglycaemia, hypoglycaemia, and glycaemic variability may be solved with the help 
of continuous glucose monitoring (CGM) devices. CGM sensors have a higher rate of BG measurement, 
and have been effective in managing diabetes, while offering potential benefits for use in the intensive 
care unit (ICU). Use of CGM devices in the ICU has been limited, primarily due to the higher point 
accuracy errors over currently used traditional intermittent blood glucose measures. General models of 
CGM errors, including drift and random errors, are lacking, but would enable better design of protocols 
to safely and effectively utilise these devices as integrated parts of GC protocols. 
 
This research presents an auto-regressive (AR) based modelling method that separately characterises 
the drift and random noise of the GlySure CGM sensor (GlySure LLC, UK). Clinical sensor data (n=33) 
and reference measurements were used to generate 2 AR models to describe sensor drift and noise. 
These models were used to generate 100 Monte-Carlo simulations based on reference blood glucose 
measurements. These simulated CGM traces were then compared to the original CGM clinical data 
using mean absolute relative difference (MARD) and a Trend Compass. The point accuracy MARD 
was very similar between simulated and clinical data (9.6% vs 9.9%). A Trend Compass was used to 
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assess trend accuracy, and found simulated and clinical sensor profiles were similar (simulated trend 
index 11.4° vs. clinical trend index 10.9°). 
 
The model and method accurately represents cohort sensor behaviour over patients, providing a general 
modelling approach to any such sensor by separately characterising each type of error that can arise in 
the data. Overall, it enables better protocol design using validated virtual patients based on accurate 
expected CGM sensor behaviour, as well as enabling the analysis of what level of each type of sensor 
error would be necessary to obtain desired glycaemic control safety and performance with a given 
protocol. 
 
The modelling of CGM sensors may then be used for in-silico virtual trials to replace intermittent 
measurements in GC. This research aims to delineate the trade-offs of performance, safety and workload 
that CGM sensors provide in GC protocols. Clinical data from 236 patients were used for clinically 
validated virtual trials. A CGM-enabled version of the STAR GC protocol was used to evaluate the use 
of guard rails and rolling windows. Safety was assessed through percentage of patients who had a severe 
hypoglycaemic episode (BG < 2.22 mmol/L) as well as percentage of resampled BG < 4.0 mmol/L. 
Performance was assessed as percentage of resampled measurements in the 4.4-7.0 mmol/L and the 
4.4-8.0 mmol/L target bands. Workload was measured by number of manual BG measures per day. 
 
CGM-enabled versions of STAR decreased the number of required blood draws by up to 74%, while 
maintaining performance (76.6% BG measurements in the 4.4-7.0 mmol/L range vs. 62.8% clinically, 
87.9% in the 4.4-8.0 mmol/L range vs. 83.7% clinically) and maintaining patient safety (1.13% of 
patients experienced a severe hypoglycaemic event vs. 0.85% clinically, 1.37% of BG measurements 
were less than 4.0 mmol/L vs. 0.51% clinically). CGM sensor traces were simulated in virtual trials and 
used in place of intermittent BG measurements to guide GC interventions and decisions. Existing GC 
protocols, such as STAR, may only need to be adjusted slightly to gain the benefits of the increased 
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temporal measurements of CGM sensors, through which workload may be significantly decreased while 
maintaining GC performance and safety. 
 
This research also reviews differences in the reporting of BG level and its variability in literature, which 
is a growing issue with the emergence of CGM sensors and other high rate sensors. There are already a 
multitude of differences in the reporting of BG level and variability where only intermittent 
measurements are concerned. The rise of new high rate sensing technology can add more temporal 
factors that also need to be considered, but also adds to the differences of reporting of BG and 
variability. The research then proposes a vision for improved description of glycaemia and how it 
changes and evolves over time. This work then presents a continuous glucose monitoring sensor-based 
method to better quantify glycaemic level and variability, based on clinically defined metrics. A case 
study of this new method is presented using CGM sensor data from a study of 614 infants at risk of 
neonatal hypoglycaemia. The CGM sensor data is used to understand glycaemia and how it evolves 
over time in an infant cohort. Results show the new clinically defined method is able to describe changes 
in glycaemic level and variability in these patients and presents a flexible way forward for accurately 
describing state and variability from a clinically defined perspective. This method may provide better 
insight to patient glycaemia over time, and thus provide scope for improved control of glycaemia. The 
metric is then used to assess glycaemic State Changes in the infant cohort, and attempts to relate the 
number of State Changes per Day to neurodevelopmental impairment data from the original study from 
which this infant cohort data is provided (the CHYLD Study). State Changes per Day as a metric for 
variability alone was found to be a weak indicator of neurodevelopmental impairment, mostly due to 
the complex behaviour experienced by the infants recovering from hypoglycaemia identified as having 
impairment. 
 
Overall, this thesis has approached the problem of using CGM sensors to understand glycaemia and its 
evolution over time, and to inform model-based, personalised GC. It develops and validates a novel and 
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accurate CGM sensor modelling method. It uses this methodology in redesigning a successful model-
based GC protocol for optimised use with CGM sensors. Finally, it presents and validates a method of 
evaluating trends and variability in high rate CGM sensor data that results from CGM enabled GC. 
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Chapter 1 Clinical Introduction 
1.1 Physiology and Impact of Hyperglycaemia 
Critically ill patients commonly experience stress induced insulin resistance resulting in 
hyperglycaemia [1-7]. Events such as major trauma and surgery cause counter-regulatory hormones 
such as cortisol, glucagon, catecholamines and growth hormone to be significantly elevated [8-11]. The 
elevation of these hormones cause increased hepatic glucose production, inhibition of insulin secretion 
and peripheral insulin resistance [11], resulting in increased blood glucose (BG) concentrations, even 
for patients with no prior history of diabetes. 
 
Studies have shown that there is a strong association between hyperglycaemia and intensive care unit 
(ICU) mortality and morbidity [1, 3, 6, 12]. Hyperglycaemia can also lead to further complications 
including myocardial infarction [1], sepsis and infection [13-17],  polyneuropathy, and multiple organ 
failure [2]. It also has been observed to induce oxidative stress and endothelial and microcirculation 
dysfunction [18], both of which contribute to organ failure [19, 20]. Thus, controlling glycaemia to 
normal levels may be key to reducing these negative outcomes in this clinical cohort.  
 
Glycaemic variability alone has also been shown to result in negative clinical outcomes [21-26]. This 
glycaemic variability is a result of various factors, including intra-patient variability due to 
unpredictable patient state or response to care, and also can be a result of poor control causing erratic 
changes in BG. In addition, hypoglycaemia has also been associated with poor clinical outcomes, 
independently of glycaemic variability [23, 26-29]. Hypoglycaemia appears more directly detrimental 
to patients than hyperglycaemia [26]. As such, any control of level and variability of glycaemia needs 
to be carefully designed as to not decrease BG too much while it is already low by normal physiological 




1.2 Clinical Care and Control 
Clinical studies have shown insulin therapy can improve patient outcomes [2, 7, 35, 36]. However, 
several studies failed to replicate early beneficial results [15, 37-39], while others showed beneficial 
outcomes [40, 41] and several showed no benefit or harm [30, 42, 43]. Overall, one large randomised 
trial in 2009 reporting adverse outcomes has become a point of reference for many rejecting glycaemic 
control (GC) [39, 44]. 
 
In theory, insulin therapy should directly counteract each of the mechanisms of injury associated with 
hyperglycaemia, reducing inflammation and infection, protecting endothelial cells and reducing 
oxidative stress. The physiological evidence suggests safe, effective glycaemic control should benefit 
all patients in the ICU through reduced blood glucose (BG) and the insulin hormone itself [5, 45-47].  
However, for many of the studies, factors such as BG variability, inter- and intra-patient variability, and 
hypoglycaemia have made good GC hard to achieve and very difficult to deliver safely, effectively and 
consistently. These factors are prevalent in the studies for which intensive GC has resulted in worse 
outcomes than more traditional GC. They confound study outcomes and comparisons across studies, 
making it hard to deduce the optimal level and method of control.  
 
Only one study, of all reported, reduced hypoglycaemia and improved outcomes with insulin therapy 
for GC [36], indicating poor control, rather than GC itself may be the cause of the variability in study 
outcomes. A recent study of metabolic variability and mortality outcomes showed no difference in 
underlying metabolic variability between survivors and non-survivors [32], suggesting patient 
outcomes are a function of the quality of control delivered and not patient-specific or cohort-specific 
characteristics. Poorly delivered control might thus affect study outcomes when looking for benefit or 
harm, as studies show good GC may need to be achieved for essentially all patients to show benefit 
[48]. As such, there is a clear need for good control algorithms able to directly manage the significant 
intra- and inter- patient variability that makes GC difficult [49-53] to provide safe, effective control for 
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all patients.  
 
Model-based methods have been developed to achieve this goal [34, 41, 54-56]. In particular, model-
based methods monitor and respond to changes in patient-specific metabolic condition, typically using 
an insulin sensitivity parameter. Insulin sensitivity is a key determinant of the glucose uptake response 
to an insulin dose, and this sensitivity is most variable early in the ICU stay where most hypoglycaemia 
occurs [23], both in response to patient condition and clinical interventions [24, 57-59]. Hence, it is a 
key factor in managing glycaemia and patient variability [50-53]. 
 
1.3 Glycaemic Control in the Christchurch Hospital ICU 
The Specialised Relative Insulin Nutrition Tables (SPRINT) protocol was a model-derived paper-based 
GC protocol developed jointly by the Christchurch hospital ICU and the University of Canterbury 
Bioengineering department. The GC protocol was able to achieve good control with significantly 
reduced incidence of hypoglycaemia in comparison to the previous standards of practice within the 
Christchurch hospital ICU [36, 48, 60]. Under the SPRINT protocol reduced mortality and organ failure 
was observed, suggesting glycaemic control provides outcome benefits to ICU patients [48]. 
 
More recently, STAR (Stochastic TARgeted), a computerised model-based protocol utilising stochastic 
models to forecast glycaemic outcomes for a given insulin and nutrition intervention, has replaced 
SPRINT as the standard of care within the Christchurch hospital ICU. STAR was shown to reduce the 
incidence of hypoglycaemia, and increase nutrition rates in comparison to SPRINT [34, 61, 62]. STAR 
also reduced clinical workload, with the average number of BG measurements taken by a nurse in STAR 




The STAR protocol has been further developed to create the STOMP (STOchastic Model Predictive) 
controller, a protocol similar to STAR that formalises the control methodology using model predictive 
control theory. The protocol utilises cost functions to determine optimal nutrition-insulin interventions 
and was able to reduce required BG measurement frequency while also increasing ease of controller 
tuning. The controller has been developed and tested in-silico and is awaiting clinical trials for further 
validation [63]. 
 
1.4 Challenges to Glycaemic Control 
However, while the future looks optimistic for model-based GC and patient outcomes [44], there is still 
much debate over what GC targets are appropriate and/or safe for an ICU context [39]. Many clinicians 
prefer higher targets out of fear of hypoglycaemia [26-29]. In contrast, most studies which have shown 
benefit have shown it from using lower targets [25, 40, 64, 65]. Further, additional evidence suggests 
these targets may be patient specific and/or differ between ICU cohorts [66]. Confounding this issue is 
a lack of consensus on how to measure and/or report GC outcomes and variability at a cohort and patient 
level [30, 67]. 
 
Workload in the ICU also has a significant impact on the clinical efficacy and compliance of glycaemic 
control. Many studies and pilot trials have reported the extra clinical effort required to implement 
intensive insulin therapy in ICUs [68-74]. This issue is especially valid in ICUs where a single nurse is 
responsible for multiple patients simultaneously [68]. Clinical incompliance to a particular GC protocol 
may result in a reduction in performance and safety, resulting in more adverse outcomes. Thus, nurse 
workload often has a direct effect on protocol compliance, and thus GC performance and clinical 
outcomes, where labour intensive but otherwise ‘good’ GC protocols are unlikely to be clinical 




Some researchers believe an upcoming technology, continuous glucose monitoring (CGM) sensors, 
would solve many of these issues of measuring and mitigating both variability and hypoglycaemia, and 
also decreasing nurse workload. CGM sensors have a far higher measurement frequency than the 
intermittent point-of-care (POC) BG measurements, which are the current standard for GC. This higher 
measurement frequency can allow better identification and quantification of variability in BG, as well 
as the ability to identify hypoglycaemia much faster than intermittent measurements. Both of the factors 
would, in theory, combine to make GC easier. However, difficulties in control still remain, and CGM 
sensor technology has not yet been shown to solve all of the issues of measurement and control that 
researchers would have liked. 
 
1.5 Preface 
This chapter provides the background for the clinical problem addressed here. Specifically, this thesis 
evaluates the advantages and disadvantages of using CGM sensors for GC in the ICU, and also for 
analysis of glycaemic state in infants at risk of hypoglycaemia in the first two days of birth. The first 
part of this thesis seeks to evaluate and model the different types of errors that can be included in CGM 
sensor measurements. The sensor model is then used to simulate the sensor in a virtual GC environment, 
to evaluate the trade-offs between safety, performance and workload for clinicians in the ICU when 
using CGM sensors to guide GC, compared to traditional intermittent POC measurements. 
 
The second part of this thesis aims to evaluate the current metrics used to evaluate glycaemic variability, 
and presents a novel method for quantifying state and variability from CGM sensor traces. It presents 
the test cases for a cohort of new born infants at risk of hypoglycaemia, in the first 48 hours of their 
birth. The method is then tested using ROC curves to determine if the changes in state or variability 




Chapter 2 reviews the current metrics used to characterise and measure glycaemic variability, and 
presents the advantages and disadvantages of using each different metric.  
 
Chapter 3 presents the background of CGM sensors that have been developed recently, particularly in 
the last decade, and assesses their use in clinical settings to date. The potential for the incorporation of 
a CGM device into the STAR GC protocol is proposed, and alternative control approaches are also 
presented. 
 
Chapter 4 develops an autoregressive model for a CGM using two orders, one for the half hourly drift 
experienced by most CGM sensors, and another to model the sensor fluctuations that are present in 
CGM sensor readings. These models, as well as the probability noise models for both sensor drift and 
sensor flux, are presented. 
 
Chapter 5 presents the results from simulating a CGM sensor and using the simulated measurements 
to guide GC in a virtual environment. The trade-off between GC safety, performance and workload are 
assessed against results from traditional intermittent POC guided GC. 
 
Chapter 6 develops a method for characterising glycaemic variability from CGM sensor traces. The 
method is applied to a cohort of infants being glycaemically monitored in the first 48 hours since birth. 
Glycaemic States are characterised for each infant retrospectively, and examples of the method and 
characterisation are presented. 
 
Chapter 7 examines the correlation between Glycaemic State Changes and negative neurologic 
development outcomes for the same infant cohort. Receiver operating characteristic (ROC) curves are 
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generated for the cohort to determine if there is any correlation between the number of State Changes 
experienced in the first 48 hours since birth, and neurologic impairment at 2 years old or 4.5 years old. 
 
Chapter 8 summarises the work carried in this thesis, and presents the major conclusions from this 
research. 
 





Chapter 2 Glycaemic Variability 
2.1 Measures of Glycaemic Variability 
Though perhaps qualitatively intuitive, glycaemic variability is difficult to effectively quantify. Many 
reviews have tried to summarise the extensive range of glycaemic variability measures, particularly in 
the context of diabetes management, as well as to more fully describe their advantages and limitations 
[75-78]. Many metrics, and adaptations of metrics, exist, but in general most fall into the following 
broad categories: 1) descriptors of middle and range; 2) descriptors of total or summed variability or 
excursion length; and 3) descriptors of time in range. 
 
 The most standard methods for describing and quantifying glycaemic variability are statistical 
descriptors of middle and range in data. The most common descriptor of variability is to report the 
standard deviation (SD) of BG measurements alongside the mean BG value [79]. Similarly, the IQR 
(inter-quartile range) is a non-parametric alternative, reported alongside the non-parametric median BG. 
These metrics are popular because of their ease of use [75]. However, the very commonly used SD is a 
measure of dispersion, rather than variability, and is limited in its ability to reflect the time course of 
BG measurements [80]. 
 
The limitations of SD for describing glycaemic variability are shown in Figure 2.1, where the mean and 
SD are the same for two time courses of intermittent BG measurements. In this case, the same set of 
BG measurements is arranged in two different patterns, one a decrease at a constant rate, and the other 
moves between extremes. Because both have exactly the same measurement set, both have the same 
mean and SD. If glycaemic variability is more truly a function of the change in BG, with more rapid 
changes exerting different physiological effects than slower changes, than patient outcomes could differ 
in these two cases. Thus, the SD is extremely limited in its ability to describe the time course of 




Figure 2.1: Two sensor traces with accompanying intermittent BG measures. The intermittent 
BG measures are the same between the two data sets, and so have the same mean and standard 
deviations, but display differing behaviours. 
 
In addition, the mean and SD assume a normal distribution, which is inaccurate as BG is usually highly 
lognormal and skewed. Thus, this measure for variability may be inappropriate to use, particularly if 
there are a large number of measurements near the hypoglycaemic range of BG. Equally, all such 
measures requiring a normal distribution assumption have this issue, and recent reviews recommend 
non-parametric statistics [30]. 
 
The Coefficient of Variability (CoV), which is the mean divided by the standard deviation, is for some 
a preferred measure of glycaemic variability [75]. CoV can be a good measure of overall glycaemic 
variability, as research has shown aiming for a CoV lower than a certain threshold (36%) allows for the 
distinction between stable and unstable glycaemia [81, 82], where glycaemic stability is also difficult 
to quantify.  However, this metric suffers the same limitations discussed regarding the mean and SD 




Metrics that look at total glucose excursion include Area under the BG curve (AUC) and Glucose Miles. 
AUC or area around a line is common in diabetes and non-critically ill cohort studies. It is often used 
with more frequently sampled continuous glucose monitoring (CGM) sensors [83-85]. Two zig-zagging 
sensor traces could theoretically have the same area, even though one trace is rising in level, while the 
other is falling. This behaviour would suggest the two traces have the same level of variability, but with 
differing behaviours, indicating how AUC is an overall measure of variance, but not specific to time 
course.  This issue is also illustrated in Figure 2.2. 
 
Glucose Miles is another way to measure variability, measuring the total ‘distance’ travelled by 
movements in BG through intermittent BG or CGM traces. It is embedded as part of some other 
measures [86, 87]. However, two traces can have the same Glucose Miles with very different mean BG, 
as shown in Figure 2.3 for a bias, and Figure 2.2 where the median is the same. Thus, this metric is 
similar to AUC in giving a total, but is not specific or reflective of the time-varying behaviour of blood 
glucose. 
 
Furthermore, while Glucose Miles and AUC can be useful descriptors of cohort variability when paired 
with measurements of mean or median BG, both are unable to describe variation away from some longer 
term average or glycaemic state, which may be important to recognise clinically. Similar metrics, more 
suited to intermittent BG measurements, include the mean absolute difference (MAD), or mean of daily 
differences (MODD) [88, 89]. Such metrics describe the average change in BG, or the difference in BG 
between days, but are limited in their ability to comprehensively describe the time course of variability 





Figure 2.2: Two sensor traces with very similar AUC, but differing behaviours. 
 
Figure 2.3: Two sensor traces with similar Glucose Miles, but with very different mean BG. 
 
Time in band is another typical measure of variance, good for combining and capturing level and 
variability. However, it tends to be more of an implicit measurement of variability, rather than an 
explicit one. It is a good aggregate measure for larger cohorts where central tendency makes time in 
band informative of overall cohort behaviour. Research has shown time in band, or time in range, can 





However, whether the measurement is inside or outside of the band itself is discrete or binary. Thus, all 
variability or measures in the band are assumed to be clinically acceptable, and those outside are not. 
Thus, a measure just inside the band is thus treated very different in analysis to one just outside, when 
both could be within measurement error. In addition, there is no agreement on appropriate bands, 
leading to difficulty in comparing the variability across studies [30]. By example, Figure 2.4 shows two 
sensor traces for a 4.4 mmol/L to 8.0 mmol/L range, which have the same time in band, but different, 
potentially clinically important behaviours both within and outside the band.  
 
Figure 2.4: Two sensor traces with similar time in band, but differing clinical behaviour. 
 
Other metrics for describing glycaemic variability exist, such as the mean amplitude of glucose 
excursions (MAGE), M-value, J-index, Low Blood Glucose Index (LBGI), High Blood Glucose Index 
(HBGI) and Average Daily Risk Range (ADRR) [75-78, 92]. Each of these metrics attempts to 
compensate for some aspect of the limitations of the metrics previously discussed, and specifically 
attempt to take into account aspects of desirable glucose outcomes. Most of these metrics involves one 
or more aspects of the middle-range, time in band, or excursion size categories. All require some degree 
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of correlation with outcomes to be clinically applicable, and have shown some degree of predictive 
capability [92]. While their disadvantages are presented elsewhere [75-78], the overall disadvantage of 
such metrics is that calculation and interpretation of these metrics is not transparent or intuitive to those 
unfamiliar with the metric, and this aspect may have impeded widespread clinical uptake. 
 
Furthermore, most of these glycaemic variability metrics have been derived using point glucose 
measurements, and most have only been validated using these intermittent BG measurements to check 
the correlation with adverse outcomes. One of the metrics has been validated using CGM sensors, and 
was found to be correlated with increased hypoglycaemia given the measure of glycaemic variability 
over some threshold [82]. However, more studies are needed for CGM sensor derived metrics and 
correlation with adverse outcomes. 
 
In addition to the various existing metrics for variability, variability in itself has been particularly hard 
to define in terms of what is clinically relevant. For example, observing the two sensor traces in Figure 
2.1, on the timescale presented of 10 hours, the two sensor traces clearly have two differing levels of 
variability. Specifically, CGM sensor trace 1 is far less variable than CGM sensor trace 2. However, 
stretching the timescale to a 24 hour period, the two sensor traces could be interpreted in a clinical sense 
as having similar variability. Thus, there are currently no metrics that can adapt their timescales to take 
into account the full time course information CGM sensors can provide. 
 
Table 2.1 presents a summary of all the metrics describing glycaemic variability. Their definitions and 












- Limited in its ability to describe the time 
course of glycaemic variability. 
- Assumes a normal distribution, whereas BG 






- Limited in its ability to describe the time 
course of glycaemic variability. 
- Assumes a normal distribution, whereas BG 
is normally lognormal. 
Area under Curve Integrated area under 
CGM sensor trace. 
An overall measure of variance, but not 
specific to time course as two traces could 
have the same area, but different behaviours. 
Glucose Miles Total glucose excursion 
by the CGM sensor 
trace. 
An overall measure of variance, but not 
specific to time course as two traces could 
have the same distance travelled, but different 
behaviours. 
Mean of Daily 
Differences (MODD), 
MAD and similar. 
Describe the average 
change in BG or 
difference in BG 
between days. 
Limited in its ability to describe the time 
course of glycaemic variability and its 
relationship with level. 
 
Time in Band (TiB) Calculate the percentage 
of glucose 
measurements within a 
desired band. 
- No agreement on appropriate band. 




In summary, the large range of glucose metric definitions are confusing, contentious, and complicated. 
No metric adequately describes the time-course of glycaemia. Variability in particular is poorly 
captured by commonly used metrics, most of which are mathematically, rather than clinically, centred 
and defined. These limitations are particularly important in the context of emerging CGM technologies, 
which provide greater time resolution with increasingly enhanced point accuracy [93]. CGMs thus offer 
the potential to significantly improve GC. However, to obtain this benefit, the best clinically defined 
metrics to capture patient glycaemic level and state must be established, which may require a new 




Chapter 3 CGM Technology 
3.1 CGM Device Background 
CGM devices show significant as yet untapped potential for improving glycaemic monitoring and 
control in the ICU, particularly due to their high measurement frequency. CGM sensors measure BG 
near continuously, with new generation devices able to measure at a rate of 1-6 times per minute [93-
96], and standard devices providing measurements every 5 minutes [97-100]. Compared to 1-6 hourly 
point-of-care (POC) measurements in a well-staffed ICU [101], these devices offer huge potential to 
improve care and reduce workload. 
 
The increased measurement frequency has many benefits for care, including the ability to monitor 
patient condition and, importantly, the trajectory of their condition in real time. They also provide 
warning for hypoglycaemic events [87, 102], allowing early correction. Both benefits cannot be 
achieved with intermittent BG measures, where the minimum clinically feasible regular measurement 
interval is ~1 hour. However, clinical non-compliance can be high even at lesser rates [103-105], as 
seen in a recent study where protocolised measurement interval was 1 hour and the clinical measurement 
was closer to 3 hours [31, 39]. 
 
Even at a 1-hour interval, a patient’s condition may change significantly between hourly POC BG 
measures. These rapid changes can result in hypoglycaemia remaining untreated for 50 minutes or 
longer. Equally, sudden changes resulting in hyperglycaemia, indicating change in patient state, can be 
missed as well [106]. A CGM sensor, on the other hand, can alarm both at occurrence and predictively 
before it occurs, reducing risk, and potentially improving and personalising care. 
 
Despite these advantages, CGM sensors are not widely used in the ICU as CGM sensor technology still 
suffers limitations, including larger point error inaccuracies and sensor drift [107-114]. They are also 
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expensive, so it may be hard to justify the cost versus potential benefits. The larger point accuracy errors 
over traditional intermittent BG measurement techniques have been well documented, with new CGM 
devices usually reporting gradually improving MARD values down to 8-12% [93, 115-117] as the 
technology has developed [93, 95, 98, 109, 115-125]. These values still do not match the 5% or lower 
errors common in intermittent POC measures [126]. Sensor drift is also still not widely recognised, 
even though it has shown to be a key driver of larger MARD and potential hypoglycaemia when used 
in GC [107, 127]. 
 
CGM technology also has the potential to reduce GC related workload in the ICU, providing more 
bedside data with lower blood sampling requirements [127-130]. Clinical practices have cited high 
workload as a reason for reduced intermittent BG measures, as not every ICU has a low enough patient 
to staff ratio to justify the increased workload some GC protocols may require [68, 70, 71]. CGM 
sensors are able to give a continuous readout of the current BG measurement, and clinicians can then 
adjust nutrition and insulin accordingly. Reduced workload and risk may also make GC more 
ergonomic and feasible in terms of direct and indirect burden on clinical staff [103]. However, this 
benefit has not yet reached regular care due to the limitations. 
 
3.2 CGM Devices and their Use to Date 
Various types of continuous glucose monitoring (CGM) device [100, 121, 131-133] have been 
developed over the last decade to continuously monitor BG and reduce measurement and sampling 
frequency. Further research into CGM devices has led to some sensors being implemented in clinical 
trials [79, 117, 123].  However, some recently developed CGM devices still have significant limitations 




Multiple types of CGM devices have been developed differing in the site and science used for BG 
monitoring. Minimally invasive subcutaneous CGM devices have been developed primarily for use in 
type I diabetes subjects [134, 135]. These CGM devices have also been trialled in critically ill patients 
as substitutes or complementary sensors for intermittent BG measurements in intensive insulin therapy, 
reporting positive reductions in key areas of GC such as hypoglycaemic events and nurse workload 
[129, 130, 136-139]. 
 
In particular, Boom et al. conducted a randomized controlled trial utilising the Freestyle Navigator™ 
(Abbott Diabetes Care, Alameda, CA, USA) to guide glycaemic control in an ICU [130]. The Freestyle 
Navigator™ is one device initially designed for use in type I diabetes. Boom et al. concluded the use of 
a subcutaneous CGM device to guide insulin treatment was as safe and effective as intermittent 
measurement, and suggested designing GC protocols to work in conjunction with CGM may increase 
GC performance. 
 
Holzinger et al. conducted a randomised controlled trial testing the CGMS® System Gold™ 
(Medtronic, Northridge, CA) in an ICU setting [140]. The glycaemic control performance and safety of 
CGM devices were not directly evaluated in this study. Instead, the main aim was to evaluate the impact 
of shock requiring norepinephrine on the accuracy and reliability of continuous glucose monitoring. 
Again, this CGM device was initially designed for use in type I diabetes, but the limitations of using 
subcutaneous CGM devices in an ICU setting were explored in this study. They concluded circulatory 
shock requiring norepinephrine therapy had no influence on the accuracy and reliability of the CGM 
device in critically ill patients. 
 
Wollersheim et al. undertook a prospective clinical trial with the Medtronic Sentrino® CGM system, a 
CGM device specifically designed for use in ICU patients [95]. This CGM device showed accuracy in 
the continuous data display, with a mean absolute relative difference (MARD) of < 14%. However, due 
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to factors such as low point accuracy and prolonged data gaps, the CGM device was reported to not 
perform with satisfactory accuracy, feasibility and clinical compliance. 
 
One of the potential limitations of these CGM devices is they measure BG indirectly from interstitial 
glucose. A physiological time lag exists between the BG concentration and the interstitial glucose 
concentration due to diffusion through the capillary wall. However, studies have shown the maximum 
average time lag is around 10 minutes [141, 142]. Thus, for the purposes of GC, where the time between 
interventions may range from 1 to 3 hours, the physiological time lag between interstitial glucose and 
BG is not likely to be a source of significant error. 
 
Other types of more invasive intravascular CGM devices have been developed to measure BG directly 
via an arterial line [143-145]. Although these CGM devices are more invasive, many critically ill 
patients may already require an arterial line for other treatments. Thus, measuring BG more directly 
through this existing arterial line would provide the added benefit of more accurate BG measurements 
required for GC with no additional invasiveness. These CGM devices are not yet widely used or 
validated in ICUs, or other patients. 
 
3.3 In-Silico CGM Protocol Testing at the University of Canterbury 
A GC protocol testing framework has also been developed at the University of Canterbury 
bioengineering department to evaluate the performance and safety of GC protocols before they are 
implemented in a clinical setting. Virtual patients are used in lieu of real critically patients, which are 
generated using STAR clinical data from Christchurch Hospital ICU. Intermittent BG and insulin-
nutrition interventions are combined with the physiological model to fit an hourly insulin sensitivity 
(SI) value [146]. The result is an SI profile over time for the duration of the patient’s glycaemic control, 
which reflects their underlying metabolic responsiveness [49, 53, 147, 148]. As SI is treatment 
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independent [149-151], it can be used to simulate the results of other interventions in-silico. A virtual 
patient is thus defined by a time ranging SI profile developed from clinical data [149, 151]. This virtual 
trial method has been clinically validated on independent data, in clinical use, and in prediction of trial 
outcomes across multiple cohorts [62, 149, 150, 152]. 
 
Within this framework, there is potential to develop a virtual CGM device model for use in virtual trials 
to replace the virtual intermittent BG measurements currently utilised for the STAR protocol. A similar 
study has developed a CGM device model that simulates the measurement of BG via interstitial glucose 
of a single sensor, the FreeStyle Navigator® CGM [153]. The model incorporated diffusion of BG from 
the blood plasma to the interstitial fluid, as well as additive autoregressive moving average noise. The 
simulated sensor was built to use with a virtual GC protocol testing framework built by the University 
of Virginia. However, to date no such CGM device modelling work has been undertaken to incorporate 
the virtual CGM device with STAR or any established glycaemic control framework. 
 
3.4 Alternative CGM-based Control Approaches 
Other types of control also exist that may benefit from the enhanced temporal resolution a CGM sensor 
would provide. There are three broad categories of control, control that is reactive and looks at previous 
measurements to control level, control that is predictive and looks forward to control level, and control 
that is also predictive and looks forward, but doses on risk to directly manage variability more than 
level [30]. 
 
Reactive PID control has been trialled for GC in the past. Chee et al. [154, 155] conducted initial trials 
in a small pilot study and were not able to adequately lower glucose levels with their PID controller. 
Some of the issues encountered included sensor failure and large sensor errors. With recent 
20 
 
developments in CGM technology, the sensor error and failure rates have improved markedly, but 
accuracy may not yet be adequate for a PID control framework.  
 
A model predictive controller, such as the one used by Plank et al. [56], uses a physiological metabolic 
model to predict the future level of BG given an insulin-nutrition intervention. The benefit of this 
prediction is the glycaemic result can be determined for a range of insulin and nutrition levels, and thus 
the most appropriate intervention chosen based on goal feed levels and glucose band targets. However, 
this controller targets BG level and does not account for variability. 
 
The STAR protocol builds upon the model predictive controller by predicting future insulin sensitivity 
and its likely changes [51-53, 156, 157]. As a result, future BG and likely variability in BG outcomes 
is directly quantified, allowing the risk of hypo- and hyper-glycaemia to be directly managed in GC 
[34, 54, 61, 62, 156, 158].  Managing variability, and thus improving control, can improve mortality 
rates in the critically ill as variability is directly associated with outcome [21, 22]. The stochastic model 
built into the STAR protocol directly addresses the issue of patient variability by dosing on risk of 
hypoglycaemia to improve control and glycaemic outcomes. 
 
3.5 Summary 
Overall, CGM technology has not reached regular clinical use in ICU care, despite common acceptance 
in lower-risk outpatient type 1 diabetes care [159-163]. As CGM technology improves it will be able to 
replace intermittent measures used in the ICU today. However, with increased temporal measures and 
benefits to control, the same issues of how to quantify level and state remain. In fact, with the increased 
measurement rate of CGM technology, these issues are exacerbated as measures that work for 
intermittent measures may not be representative or accurate for use with CGMs. There thus remains a 
significant need for better, more clinically defined metrics, and in particular, those able to maximise the 
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Chapter 4 CGM Modelling 
4.1 Background  
CGM sensor technology has potential to improve GC, but the increased temporal measurement 
resolution CGM devices provide is still, at least somewhat, outweighed by the larger point accuracy 
errors in these devices due to sensor drift, bias, and random noise [108, 113, 128, 153, 164-166]. Trend 
accuracy is also an important factor, particularly where alarms indicating hypo-, and hyper-, glycaemia 
are concerned [167]. As a result, GC utilising CGM in the ICU is very uncommon, and is not yet 
standard practice anywhere, despite some studies showing it may be feasible [129, 130, 168-172]. 
 
There is thus a need to model and account for sensor error, preferably in a generalisable modelling 
method. Such a method would in turn enable optimal (model-based) design of GC protocols maximising 
CGM advantages and minimising their disadvantages in GC. It would also match recent consensus 
statements from medical and industry based working groups that measures of accuracy need to be 
standardised for licensing authorities, and to enable comparisons across studies and devices [173, 174]. 
 
Three CGM models have been developed in the past, primarily for interstitial CGM devices, by Breton 
and Kovatchev [153], Lunn et al. [113], and Facchinetti et al. [108]. The model developed by Breton 
and Kovatchev has been used in in-silico preclinical trials to simulate the effectiveness of using an 
interstitial CGM device for closed-loop control in type 1 diabetes [175, 176]. However, Facchinetti et 
al. have since shown the modelling methodology used by Breton and Kovatchev may be sensitive to 
small errors in CGM data calibration or errors in the description of BG-to-interstitial glucose (IG) 
dynamics [110]. Lunn et al. [113] developed a more refined version of the model developed by Breton 
and Kovatchev by fitting a dynamic model with forcing functions. However, it suffers from the same 
issue as Breton and Kovatchev’s model. In addition, neither model separately considered sensor drift, 
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thus including it in point error. They were thus not as accurate for sensors where drift occurs, which is 
all current approved (chemistry-based) CGM sensors. 
 
Facchinetti et al. further developed a model of sensor error incorporating BG-to-IG dynamics, using an 
autoregressive model to account for additive measurement noise and a linear time-varying model to 
account for calibration and sensor drift [108]. Again, BG-to-IG dynamics are added because the CGM 
device modelled was an interstitial device. This modelling method was able to account for sensor drift, 
and also split sensor error into multiple components, including error arising from calibration and 
measurement noise. However, this modelling method is very data and labour intensive, requiring 
multiple CGM devices per patient and 15 minute intermittent BG measurement intervals. This large 
amount of data may not be available in past data acquired from CGM device trials, while the large 
workload required to measure BG every 15 minutes would be a clinical and feasibility barrier for further 
sensor error characterisation [70, 71, 104, 105], and thus to modelling and simulation of sensor 
behaviour in new CGM devices. 
 
Additionally, none of the previous modelling efforts have taken into account trend accuracy of the CGM 
devices studied. Signal et al. [167] developed the Trend Compass and Trend Index to assess a CGM 
sensor’s trend accuracy. In particular, trend accuracy could be seen as equally or more important as the 
measurement of mean absolute relative difference (MARD) to assess point accuracy in the previous 
modelling efforts, especially because trends are often used in clinical decision making. 
 
The GlySure (GlySure Limited, UK) CGM device considered in this work is from a newer class of ICU 
devices measuring venous BG via an intravenous line, thus avoiding IG dynamics. The sensor is 
comprised of microporous and dialysis membrane, hydrogel, optical fibre and a thermocouple, while 
the glucose detecting chemistry used is a fluorescent diboronic acid receptor, embedded within the 
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hydrogel. Placement of the sensor itself can occur through either a central venous catheter, or a radial 
artery catheter [93]. 
 
This chapter presents a novel auto-regressive (AR) method and model characterising this CGM sensor. 
The modelling method is capable of characterising the CGM sensor with less data than required by 
previous characterisation methods in terms of sensors per patient, and explicitly accounts for sensor 
drift, while maintaining both the point and trend accuracy of simulated sensor errors. This model is 
developed and compared to clinical data to assess its validity. The overall modelling method and 
approach is generalisable to similar devices.  
 
4.2 Methods 
4.2.1 Sensor Modelling 
4.2.1.1 Clinical Data 
 
Data was sourced from an observational pilot trial of the CGM device on 33 cardiac intensive care 
patients (duration 21-51 hours per patient), where CGM readings were not used clinically for GC. The 
sensor provides a new reading 4 times per minute, and intermittent BG measures are used to calibrate 
the sensor (calibration or recalibration BG) approximately every 8 hours. Intermittent independent BG 
measures not used to calibrate the sensor (reference BG) were taken approximately every 2.5 hours. 
Each intermittent BG measurement was taken using YSI 2300 STAT Plus (Yellow Springs Instruments, 
Yellow Springs, OH) or the i-STAT (Abbott Laboratories, Abbott Park, IL), which are highly accurate 
measures, in order to minimise the error in reference BG values (Mean Percentage Error of 1.79 %) 




Patient details and details of the pilot trial can be found in Table 4.1 and Table 4.2. Data from Patients 
10 and 22 were later discarded due to sensor failure. The mean absolute relative difference (MARD) 
was calculated between paired BG (calibration and reference) and CGM measurements. The average 
global MARD (excluding Patients 10 and 22) was 9.6%.  
 
Table 4.1: Patient details from the Glysure CGM sensor clinical trial. The mean (range) is 
reported for the Duration, BMI and Age. 
Characteristic Cardiac patients 
n 33 
Duration (hours) 40.8 (21.1-50.7) 
Male 22 (66.7%) 
Female 11 (33.3%) 
Individuals with Diagnosed Diabetes 14 (42.4%) 
Hypertensive 15 (45.5%) 
BMI 25.3 (17.7-35.8) 
Age 50.8 (19-77) 
 
4.2.1.2 Sensor Characterisation 
Sensor characterisation uses two independently defined AR models to separately capture drift and 
higher frequency sensor fluctuations, where most other methods have not explicitly accounted for 
sensor drift [113, 153]. This method is able to be used on the clinical data where there was only one 
CGM sensor per patient, which would not have been possible with the method of [108], as the 












Table 4.2: Pilot trial details. 









MARD Median [IQR] 
Sensor Error (%) 
1 48.33 3 14 8.62 8.4 [4.6 12.3] 
2 40.97 3 13 6.20 5.1 [1.7 10.4] 
3 42.66 3 13 6.00 2.9 [1.7 9.4] 
4 47.33 2 15 10.66 9.7 [6.3 14.3] 
5 47.05 3 15 6.85 4.6 [2.0 11.2] 
6 50.69 3 14 9.57 9.3 [7.8 10.8] 
7 46.90 3 14 12.56 13.3 [6.5 16.8] 
8 43.43 3 14 4.47 2.7 [1.7 5.9] 
9 47.05 7 14 13.25 10.9 [3.5 18.2] 
10   - - - - - 
11 48.69 3 15 15.62 8.5 [4.1 11.2] 
12 42.84 3 13 11.73 6.1 [1.5 12.0] 
13 40.91 3 12 6.10 14.5 [10.8 25.4] 
14 45.60 4 13 12.10 13.0 [8.1 21.3] 
15 39.37 5 10 4.60 12.8 [6.0 18.3] 
16 43.51 7 9 6.43 6.9 [2.7 13.7] 
17 37.71 3 12 7.48 10.3 [6.1 21.5] 
18 36.72 5 11 7.84 11.3 [9.1 15.7] 
19 39.23 2 13 4.85 4.5 [2.7 8.5] 
20 40.42 4 11 7.19 4.0 [2.3 7.2] 
21 36.35 4 11 8.27 7.2 [4.0 7.9] 
22 - - - - - 
23 37.77 3 13 5.29 6.0 [2.7 10.3] 
24 39.03 4 12 12.20 3.5 [1.5 8.0] 
25 38.12 3 13 4.77 12.8 [5.0 17.4] 
26 36.69 3 12 6.22 4.4 [2.2 6.4] 
27 40.12 4 12 12.36 4.7 [3.2 7.7] 
28 37.65 4 12 14.49 8.5 [7.7 16.0] 
29 37.81 3 12 22.93 16.5 [9.7 20.9] 
30 36.51 4 11 10.12 21.9 [18.5 27.7] 
31 37.54 4 12 8.19 8.3 [3.3 13.9] 
32 21.14 2 7 17.38 7.0 [3.4 11.8] 
33 25.49 3 9 14.35 14.0 [11.9 17.7] 
Overall Cohort 




3 (2 - 7) 12 (7 - 15) 8.27 (4.47 
- 22.93) 
- 
*Patients 10 and 22 were discarded in this retrospective analysis due to sensor failure 
 
A. Drift: 
Clinical data is divided into separate periods between recalibration points for each patient. Drift is 
characterised for any given patient trace between recalibration measurements using the percentage 
difference between sensor and reference measurements, as assessed half-hourly using sensor glucose 
(SG) (𝐵𝐺𝑆𝐺/30 𝑚𝑖𝑛), and intermittent BG interpolated (𝐵𝐺𝐼𝑀/30 𝑚𝑖𝑛) between calibration and reference 
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measurements (𝐵𝐺𝐼𝑀). Interpolated intermittent BGIM measures are a vector with an interpolated value 
every 30 minutes, defined: 
 
𝐵𝐺𝐼𝑀/30 𝑚𝑖𝑛 = 𝑖𝑛𝑡𝑒𝑟𝑝(𝐵𝐺𝐼𝑀)|𝑡=0:30:𝑡𝑒𝑛𝑑   (4.1) 
 
Half hourly sampling of the CGM sensor trace simply takes the paired CGM value at that time: 
 
𝐵𝐺𝑆𝐺/30 𝑚𝑖𝑛 = 𝑠𝑎𝑚𝑝𝑙𝑒(𝐵𝐺𝑠𝑒𝑛𝑠𝑜𝑟)|𝑡=0:30:𝑡𝑒𝑛𝑑   (4.2) 
 
The half hourly interval matches observed physiological and clinical time frames for BG fluctuations 
and trends, and thus captures the broad trends caused by sensor drift and, over several samples, 
eliminates the impact of random errors at any given point. Thus, a potential percentage drift can be 
calculated at each paired half hourly value: 
 
𝐷𝑟𝑖𝑓𝑡 =





A lag-2 AR model is then used to characterise the observed drift for a given patient’s data or for the 
whole cohort. This AR model uses the entire cohort’s data (N = 31 patients), and is defined: 
 
𝐷𝑟𝑖𝑓𝑡𝑛+1 = 𝛼𝑑 + 𝛽𝑑 ∗ 𝐷𝑟𝑖𝑓𝑡𝑛−1 + 𝛾𝑑 ∗ 𝐷𝑟𝑖𝑓𝑡𝑛 + 𝜉𝑑 
 
(4.4) 
Model parameters αd, βd and γd are identified using linear least squares from the half hourly [Driftn+1, 
Driftn, and Driftn-1] data points derived from the entire clinical data cohort (N = 31 patients) and 
Equations 4.1-4.3, assuming ξd (or drift Eta) = 0. The parameters αd, βd and γd thus capture sensor drift 




Having identified the best fit (αd, βd and γd) for the cohort, a drift noise term is calculated by re-arranging 
Equation 4.4 and solving for the residuals, ξd. Outlier drifts from Equation 4.3 of more than ±25%, 
where 99.3% of the data is within this threshold, were discarded to maintain sufficient data density for 
probability modelling. These results are used to create a drift noise model by smoothing a continuous 
distribution function across the ξd residual results obtained by rearranging Equation 4.4. 
 
B. Random Sensor Noise: 
Random sensor noise fluctuations are assessed at the CGM sensor sample rate (4 measures per minute) 
and are sampled from the interpolated BG and CGM device measurements every 15 seconds or 0.25 
minutes, yielding: 
 













Another lag-2 AR model is used to characterise these sensor fluctuations around the trend, defined: 
 
𝑆𝑒𝑛𝑠𝑜𝑟𝐹𝑙𝑢𝑥𝑛+1 = 𝛼𝑠𝑓 + 𝛽𝑠𝑓 ∗ 𝑆𝑒𝑛𝑠𝑜𝑟𝐹𝑙𝑢𝑥𝑛−1 + 𝛾𝑠𝑓 ∗ 𝑆𝑒𝑛𝑠𝑜𝑟𝐹𝑙𝑢𝑥𝑛 + 𝜉𝑠𝑓 
 
(4.7) 
The model parameters αsf, βsf and γsf are identified using the entire data cohort (N = 31 patients) and 
linear least squares from [SensorFluxn+1, SensorFluxn, and SensorFluxn-1] data points obtained every 15 
seconds (0.25 minutes), as derived from clinical data, and Equation 4.6, assuming ξsf (or sensor 




After identifying a linear best fit (αsf, βsf and γsf) across the entire data cohort, the sensor fluctuation 
noise term is calculated by re-arranging Equation 4.7 and solving for the residuals, ξsf.  Outlier 
fluctuations of more than ±1%, where 99.9% of the data is within this threshold, were discarded. These 
results are used to create a sensor fluctuation noise model, similar to the drift noise model, by smoothing 
a continuous distribution function across the data range of ξsf. 
 
C. Illustrated Example of Sensor Characterisation: 
An example of the modelling process is shown using data from Patient 2 in Figure 4.1. Figure 4.1(a) 
shows the clinical sensor data for Patient 2 over the first 16 hours, with the data split into separate 
periods between recalibration times to characterise drift. Figures 4.1(b) and 4.1(c) show characterisation 
of the AR drift model using Equations 4.3 and 4.4, where Figure 4.1(c) shows the plane of best fit for 
model parameters αd, βd and γd, and the drift noise term definition (ξd). Figures 4.1(d)-4.1(f) show 
characterisation of the sensor fluctuation model using Equations 4.6 and 4.7, with planes of best fit for 





a) Clinical data plotted for Patient 2. 
 
b) Patient 2 with BG resampled every half hour. 




c) Driftn+1 plotted against current (Driftn) and 
previous (Driftn-1) for all patients. The plane 
of best fit is shown in black, with a red arrow 
showing how the residual ξd is sampled. 
 
d) Patient 2 with BG resampled every minute. Red 
arrows show how the sensor fluctuation was 
characterised (Note small x and y scales). 
 
e) Sensor fluctuationn+1 plotted against 
current sensor fluctuation (n) and previous 
sensor fluctuation (n-1) for all patients. The 
plane of best fit is shown. 
 
f) Sensor fluctuationn+1 plotted against current 
sensor fluctuation (n) and previous sensor 
fluctuation (n-1), with a red arrow showing how the 
ξsf is sampled for the fluctuations. 
Figure 4.1: Steps of the sensor characterisation process, showing how the drift and sensor 




4.2.2 Sensor Simulation 
Sensor simulation for validation simulates a sensor trace given intermittent BGIM measures in a process 
essentially the reverse of sensor characterisation. Intermittent BGIM measures are used as a base to 
simulate the CGM sensor, as that is all the clinical data that might be available when simulating a virtual 
patient to be monitored by CGM [149, 179-181]. They are interpolated half hourly, and drift applied 
using Equation 4.4. The resulting BG with drift is defined: 
 
𝐵𝐺𝑏𝑎𝑠𝑒(𝑡=0:30:𝑡𝑒𝑛𝑑) = 𝐵𝐺𝐼𝑀/30 𝑚𝑖𝑛𝑢𝑡𝑒𝑠 ∗ (1 + 𝐷𝑟𝑖𝑓𝑡) (4.8) 
 
Where Drift is calculated using Equation 4.4, with ξd drawn randomly from the cohort probability 
distribution generated from the clinical data. At t = 0 and any calibration BG, approximately every 8 
hours for this device, the condition [Driftn, Driftn-1] = [0.0, 0.0] is used to recalibrate the CGM sensor 
to match the simulated intermittent BG measurement, providing a point to point calibration. This 
approach could be modified to account for any more complex calibration process. 
 
BGbase is then linearly interpolated to provide enough data points to match this CGM device’s 4 times 
per minute rate, such that: 
 
𝐵𝐺𝑏𝑎𝑠𝑒/0.25 𝑚𝑖𝑛𝑢𝑡𝑒𝑠 = 𝑖𝑛𝑡𝑒𝑟𝑝(𝐵𝐺𝑏𝑎𝑠𝑒)|𝑡=0:0.25:𝑡𝑒𝑛𝑑 (4.9) 
 
The simulated sensor output is then defined: 
 
𝐵𝐺𝑛𝑒𝑤_𝑠𝑒𝑛𝑠𝑜𝑟(𝑡=0:0.25:𝑡𝑒𝑛𝑑) = 𝐵𝐺𝑏𝑎𝑠𝑒/0.25 𝑚𝑖𝑛𝑢𝑡𝑒𝑠 ∗ (1 + 𝑆𝑒𝑛𝑠𝑜𝑟𝐹𝑙𝑢𝑥) (4.10) 
 
Where SensorFlux is calculated according to Equation 4.7, with ξsf drawn randomly from the cohort 




Once again, at t = 0 and any calibration BG, the condition [𝑆𝑒𝑛𝑠𝑜𝑟𝐹𝑙𝑢𝑥𝑛, 𝑆𝑒𝑛𝑠𝑜𝑟𝐹𝑙𝑢𝑥𝑛−1]  =
[0.0, 0.0] is used to recalibrate the CGM sensor. Finally, an additional limit of a maximum drift of 40% 
was applied to the drift AR model matching extremes seen in the clinical sensor data. 
 
Regarding calibration, setting [𝐷𝑟𝑖𝑓𝑡𝑛, 𝐷𝑟𝑖𝑓𝑡𝑛−1] = [0.0, 0.0] and [𝑆𝑒𝑛𝑠𝑜𝑟𝐹𝑙𝑢𝑥𝑛, 𝑆𝑒𝑛𝑠𝑜𝑟𝐹𝑙𝑢𝑥𝑛−1] =
[0.0, 0.0] effectively applies a point to point recalibration, allowing the sensor trace to go through a 
recalibration point. Divergence from the interpolated BG is then initiated by the ξd and ξsf terms. Figure 
4.2 outlines the steps during simulation, with a sensor trace and virtual patient forward simulated for 
the first 4 hours given the initial intermittent BG data in Figure 4.2(a). 
 
 
a) An example patient. Intermittent clinical BG 
measures are interpolated. 
 
b) AR drift is applied to the interpolated BG at 
half hour intervals (Equation 4.8). 
 
c) AR sensor fluctuations are added to the 
interpolated AR drift (Equations 4.9 and 4.10). 
 
d) Comparison of intermittent BG and final 
sensor simulation. 
Figure 4.2: Sensor simulation steps, calibration not shown.  
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4.2.3 Sensor Model Validation: Qualitative and Quantitative 
Sensor traces are simulated using intermittent BG from the clinical data cohort from which the model 
was built. To test consistency between the model and the clinical sensor data, several sensor simulations 
were overlaid with the clinical data for each patient trace and compared in a blinded test. If the clinical 
sensor traces were difficult to visually distinguish from simulation, then the model was qualitatively 
accepted as broadly capturing key behaviour. This qualitative assessment enables assessment of trends 
and features not easily compared in quantitative tests. 
 
To quantitatively validate the model, a single simulation was run to generate a single sensor trace from 
the sensor model for each patient to compare to the clinical sensor data. Percentage difference 
distributions for the simulated sensor data and the clinical sensor data were compared, and a Clarke 
Error Grid (CEG) plot and Bland-Altman plot constructed. The Bland-Altman plot enables analysis of 
any differences in bias behaviour between clinically measured and modelled sensor traces. Trend 
accuracy was assessed and compared for the clinical data and simulation data using the Trend Compass 
and Trend Index described by Signal et al. [167]. A Trend Compass and Trend Index, defined in 
Equation 4.11 as an absolute mean angle from perfect trend accuracy, were produced for both clinical 
and simulation data to validate the reproduction of trend accuracy using the simulation method. 
 
The Trend Compass is a visual tool that can be used to quickly identify the trend accuracy of a particular 
CGM sensor. The compass itself is split into four separate quadrants depending on the relative changes 
of BG and SG, with measurements plotted according to the angle between the interpolated BG vector 
and the corresponding CGM vector (θ), and radially according to the last interpolated BG measurement. 
The angle of theta (θ) is plotted as measured from the vertical and represents the level of agreement 
between the rates-of-change in BG and SG, where points plotted on the vertical have perfect trend 
accuracy. It thus evaluates rising (upper half) and falling (lower half) trends separately, where the two 
sides distinguish trends where CGM measured SG rises (or falls) faster or slower than BG. Figure 4.3 
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illustrates this tool in full. This quantitative validation was carried out for each patient and sensor trace 
in the clinical cohort. 
 










Figure 4.3: Six examples of SG and BG paired measurements with their corresponding point on 
the Trend Compass. Note: comparing 'A' to 'D' shows that the constant bias has no effect on 
how trending is displayed on the Trend Compass (Both examples have perfect trend accuracy so 
θ=0°). 
 
Further Monte-Carlo simulations were undertaken, until a total of 100 simulations worth of data was 
generated for each patient. Individual patient simulation traces were plotted on top of the clinical data 
to further check the consistency between the clinical data and simulated traces. The range of simulated 
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sensor behaviour was also compared to the original clinical data to ensure simulated sensor behaviour 
reflected extremes in actual sensor behaviour. For each patient, the minimum simulated BG value was 
taken for each time point over the 100 simulations to generate an overall minimum sensor profile. A 
maximum sensor profile was also produced for each patient in a similar method, using the maximum 
simulated BG values for each time point. Together, these minimum and maximum profiles formed an 
area profile of all possible simulated BG values, which were then compared to the clinical sensor traces 
for each patient. 
 
4.2.4 Convergence Analysis 
To validate this model methodology is able to work with limited reference readings, the number of 
reference BG measurements that were not recalibration measures was halved (42% less measures), and 
the sensor was re-characterised for drift and noise. The global MARD for the simulations of the sensor 




4.3.1 Sensor Characterisation 
Table 4.3 gives sensor model parameters identified from the cohort data, and Figure 4.4 shows the noise 
term model distributions (ξd and ξsf), raw and smoothed fit, for drift and sensor fluctuations. 
 





𝜶 𝜷 𝜸 𝝃 median 𝝃 max 
(absolute) 
R2 
1 Drift -0.00147 -0.07152 0.9698 -0.0023 0.2486 0.81 






(a) Noise model for drift, ξd 
 
(b) Noise model for sensor fluctuations, ξsf 
Figure 4.4: Random noise distributions for auto-regressive drift and sensor fluctuations 
(fraction). 
 
4.3.2 Sensor Simulation 
 
Figure 4.5 shows four example patients with the real sensor trace plotted alongside two simulated traces. 
Sensor behaviour is visually consistent between simulated and real sensor traces, with drift and sensor 
fluctuations of approximately the same magnitude across all traces. In a few sensor traces, such as the 
clinical data in Figures 4.5(b), there is additional high frequency low amplitude noise the model cannot 
capture. This noise is not likely to affect glycaemic control applications of this sensor, whether in 
simulation or practice. The model is thus considered qualitatively good. 
 
Figure 4.6 shows the distribution of percentage differences over all N = 31 patients clinical and 
simulation data, with one simulation per patient. The percentage differences were calculated by taking 
SG, subtracting the interpolated intermittent BG, and then dividing through by the interpolated 
intermittent BG. The model simulated data distribution is slightly tighter than the clinical data. This 
outcome is mainly due to the point-to-point recalibrations used in the simulations, which is a slightly 
more accurate recalibration than the one used in the clinical trial. There is also some slight non-Gaussian 
distribution of percentage differences at the extremes, compared to the Gaussian noise distribution used 
in the AR modelling. However, the distribution is still very similar, indicating the modelling method 





(a) Clinical sensor data plotted alongside 2 
simulations for patient 1. 
 
(b) Clinical sensor data plotted alongside 2 
simulations for patient 2. 
 
(c) Clinical sensor data plotted alongside 2 
simulations for patient 4. 
 
(d) Clinical sensor data plotted alongside 2 
simulations for patient 5. 
Figure 4.5: Clinical sensor data with two sensor traces generated from the model. 
 





The Clarke Error Grid (CEG) in Figure 4.7 shows the model behaves in a consistent manner to the 
clinical data. While the distributions are consistent across the BG range, as expected, there are a few 
outliers in the clinical data not captured by the model. The percentages of measurements falling within 
the zones of the CEG plot are shown in Table 4.4. Slightly more data points fell within zone A than 
zone B when comparing the simulated results to the clinical results, suggesting the simulation method 
may be slightly more accurate than the clinical sensor. However, this difference is minor (~6.6% change 
between zones A and B), and thus the model could still be considered to quantitatively represent the 
sensor behaviour well. In Figure 4.8, the Bland-Altman plot shows no significant bias across the 
observed BG range, and the plotted lines of ±2σ for the clinical and simulated data show the strong 
similarity between the model outputs and the clinical sensor data over this 95% range.  
 
Of note, there is very little clinical data below 5 mmol/L. Underlying sensor model assumptions apply 
constant sensor behaviour across the full BG range resulting in similar proportional BG error at high 
and low BG. This assumption is used for lack of other data from the sensor at this time. In this case, at 
lower BG, this choice translates to a consistent percentage error, resulting in slightly lower absolute BG 
errors.  
 
Figure 4.7: Clarke Error Grid plot of the clinical sensor data and the clinical simulated data, 




Table 4.4: Percentages of simulated and clinical measurements falling within the zones of the 
CEG. 
Zone Simulated Data (%) Clinical Data (%) 
A 89.3 82.7 
B 10.6 17.1 
C 0 0 
D 0.1 0.2 




Figure 4.8: Bland-Altman plot of clinical sensor data and simulated clinical data. 
 
Figure 4.9 shows the Trend Compass [167] plot for the clinical sensor data and simulated data. The 
simulated data matches the clinical data well, indicating the model captures the trend accuracy of the 
clinical sensor, as well as the point accuracy. The Trend Index, as described in Signal et al. [167], of 
the clinical sensor and simulated sensor were 10.9° and 11.4° respectively, while the IQR of the theta 
(θ) values used to evaluate the Trend Index were [3.4° 16.2°] and [4.0° 16.1°] for the clinical data and 
simulated data, respectively. The similarity between the Trend Indexes and the IQRs of theta values 
further show that the behaviour of the model is consistent with the clinical data, particularly important 
for trend simulation which has not been covered in other models. Overall, the model quantitatively 





Figure 4.9: Trend Compass plot of clinical sensor data and simulated clinical data. 
 
Table 4.5 compares the median clinical SG for each patient, as measured by the CGM sensor at each 
intermittent BG measurement time, to the average median value from the 100 model simulations of SG. 
The measured median values for each patient are comparable and differ only slightly, as shown by the 
percentage error, which had median and IQR range values of 1.2%, -1.1% and 3.1%, respectively. 
Differences are primarily due to the application of a cohort-model to individual patients, confirming 
that the model is able to capture the average sensor behaviour over the cohort well. The largest 
percentage error occurred for Patient 32, which had a clinical sensor reading that was consistently lower 
than the intermittent BG measurements. This different CGM sensor behaviour could be due to sensor 





Table 4.5: Median SG for the clinical data and the mean of the median simulated SG value over 
100 simulations for each patient. 







Median and Simulated 
Median (%) 
1 9.7 9.3 4.1 
2 6.9 6.7 2.9 
3 9.4 8.8 6.4 
4 10.1 10 1.0 
5 8.3 8.2 1.2 
6 8.6 8.7 -1.2 
7 8.1 8.2 -1.2 
8 8.6 8.8 -2.3 
9 7.9 7.8 1.3 
10 - - - 
11 8 7.7 3.8 
12 9.7 9.6 1.0 
13 10.1 10.5 -4.0 
14 7.9 8.2 -3.8 
15 9.9 10.1 -2.0 
16 9.6 9.6 0.0 
17 8.1 7.8 3.7 
18 9.7 9.5 2.1 
19 9.7 9.4 3.1 
20 11.1 11.4 -2.7 
21 9.4 9.1 3.2 
22 - - - 
23 10.2 10.2 0.0 
24 12.9 12.5 3.1 
25 8.1 7.8 3.7 
26 9 9.1 -1.1 
27 9.4 9.3 1.1 
28 10.8 10.4 3.7 
29 8.4 8.2 2.4 
30 8.9 8.6 3.4 
31 8.4 8.2 2.4 
32 9.5 11.6 -22.1 
33 8.6 8.5 1.2 
Cohort Median 
(Range) 
9.4 (6.9 – 12.9) 9.1 (6.7 – 12.5) - 
 
The average global MARD for each simulated patient trace over the 100 sensor simulations, excluding 
Patients 10 and 22, was 9.6%, where the range of the global MARD of each simulation was from 8.3% 




Figure 4.10 shows examples of four typical patients individual simulations, with the first 20 of the 100 
total simulations plotted for each patient. They each show the multitude of potential sensor traces for a 
patient given their particular intermittent BG measurements, with a single (arrow) recalibration point 
included for each patient. Note that each sensor simulation, regardless of the amount of sensor drift at 
the particular point in time, collapses to the recalibration BG at the recalibration time from the clinical 
trial, before initiating divergence again through the ξ terms in the model. 
 
 
(a) Patient 1. 
 
(b) Patient 5. 
 
(c) Patient 6. 
 
(d) Patient 8. 
Figure 4.10: 20 sensor simulations (out of 100 total) plotted for some example patients, with 
clinical reference and calibration BG plotted for reference. 
 
Figure 4.11 shows examples of the range of the simulated sensor traces plotted against the clinical CGM 
sensor data for the same 4 patients in Figure 4.10. These   plots   show   the   range   of   simulated   SG   
compared   with clinically   measured   SG   and   intermittent   BG.   This   range,   or   the   outlying   
lines,   shows   the extremes   of   the   simulated   profiles   from   100   simulations.   The   clinical   
data   fell   within   this simulated   range   for   a   large   majority   of   time   (>   95%   for   88%   of   




(a) Patient 1. 
 
(b) Patient 5. 
 
(c) Patient 6.  
(d) Patient 8. 
Figure 4.11: Clinical CGM sensor data (blue) plotted against the range profile generated with 
100 Monte-Carlo simulations (gold). 
 
4.3.3 Convergence Analysis 
Figure 4.12 shows the percentage difference distribution plot of the simulated sensor using the re-
characterised model of the reduced reference measurement data set. The plot is very similar to the plot 
of the full sensor model in Figure 4.6, where the minor differences can be explained by the random 
nature of the CGM sensor trace simulation method. Figure 4.13 also shows the CEG plot of the re-
characterised model simulation with reduced reference measurements. The plot is very similar to the 
plot of the full sensor model in Figure 4.7, while Table 4.6 gives a break down of the percentages of 
measurement pairs falling within the zones of the CEG plot. Again, the percentages are very similar to 
the percentages of the full sensor model in Table 4.4, with minor differences also being able to be 
explained by the random nature of the simulation method. The global MARD for the reduced reference 
measurement simulation was calculated to be 10.1%, which again is similar to the full sensor model 




Figure 4.12: Percentage difference distribution plot of the re-characterised model simulation 
with reduced reference measurements. 
  









Table 4.6: Percentages of simulated and clinical measurements falling within the zones of the 
CEG. 
Zone Simulated Data (%) Clinical Data (%) 
A 86.1 82.7 
B 13.7 17.1 
C 0 0 
D 0.2 0.2 
E 0 0 
 
4.4 Discussion 
4.4.1 Sensor Model 
Overall, a sensor model was developed from clinical data and simulated measured sensor behaviour 
well. The MARD, CEG plot and Trend Compass plot for the simulated sensor and the clinical data are 
very similar (MARD 9.6% vs 9.9%, Trend Index 11.4° vs. 10.9° respectively). Equally, simulated 
sensor traces were difficult to visually distinguish from clinical data, and clinical data fell within the 
simulated sensor range for a large majority of time (> 95% for 88% of patients) or all the time (70% of 
patients) for all patient profiles. Overall, results suggest the method and model are qualitatively and 
quantitatively able to describe virtually all the observed CGM sensor behaviour, including accurately 
capturing trend behaviours, which is important for future work testing the sensor in simulation for 
CGM-based protocol development and optimisation. 
 
The sensor model developed here builds on the sensor model developed by Thomas et al. [182], which 
uses a much simpler statistical model. The model developed by Thomas et al. was made from Medtronic 
Sentrino CGM sensor data from an observational pilot study of CGM sensors in patients admitted to 
the Christchurch Hospital ICU. The key differences between the two models is that the sensor model 
described in this chapter has been expanded to the lag-2 autoregressive functions to both drift and sensor 
fluctuations, described as drift and sensor noise respectively in the work presented by Thomas et al., 




This method of sensor error characterisation compares well with the method developed by Facchinetti 
et al. [108], with both methods able to achieve a similarity between the simulated global MARD and 
the global MARD from clinical studies of the respective devices studied [108, 121, 183]. The method 
presented here and the method developed by Facchinetti et al. also have the advantage of explicitly and 
independently characterising sensor drift compared to other prior models [113, 128, 153]. The method 
presented here could also be perceived as more straight-forward to implement than the method 
developed by Facchinetti et al., requiring much less data, and also could be used on existing data sets 
where only data from one CGM device per patient is available, which is currently typical. 
 
Another possible advantage of the method presented here is it may require less reference BG to 
characterise the error from a sensor and simulate sensor error compared to [108]. The clinical data had 
reference BG measurements every 1-4 hours, which were then interpolated to carry out the 
characterisation step. The clinical data Facchinetti et al used required a reference BG measurement 
every 15 minutes, possibly to enable a more accurate parameter identification of the parameters used in 
the model. While this high level of clinical data allows precise sensor characterisation, it is highly 
intensive and costly to gather and would not be available in typical clinical or regulatory trial data. 
Thus, the model created here can be more easily developed and implemented. 
 
The reproduction of trend accuracy within CGM sensor simulation is an important advantage of this 
modelling method and has not been tested on other modelling efforts in other publications. Lower trend 
accuracy in simulation than seen in the clinical sensor can result in more episodes of undetected 
hypoglycaemia, or a higher rate of false alarms than what would be seen in practice [167]. Conversely, 
higher trend accuracy in the simulated sensor than in the clinical device would hide the number of 
missed hypoglycaemic events and give a lower rate of false alarms than what would occur in practice, 
making the simulation performance seem much better than clinical performance. It is thus a critical 
feature overlooked by other methods. Both scenarios are mitigated in this case by reproducing the   




A key result of having a model and generalisable sensor modelling method for a CGM sensor that 
accurately reproduces point accuracy and trend accuracy, is being able to test the effects of using CGM 
sensor readings in place of intermittent BG readings during GC in a virtual patient environment. The 
model can then be used in virtual patient trials to optimise a CGM-enabled GC protocol for any 
characterised CGM sensor. More importantly, such models, and a generalisable method for making 
them, also enable the ability to assess what level of CGM performance makes the technology feasible 
in the ICU to safely improve care and reduce workload. 
 
New developments in CGM devices also have resulted in BG being measured at a higher frequency, 
such as the device used in this study that is able to measure BG 4 times per minute. A benefit of the 
model presented here is the ability to capture both the fast and slow random error dynamics of the CGM 
device. The capturing frequency can be adjusted to match the measurement frequency of other CGM 
devices that are to have the sensor errors characterised and simulated. 
 
4.4.2 Limitations 
One of the limitations of this study is the limited BG < 5.0 mmol/L in the clinical data used to construct 
the model. As a result, use of this model outside the BG range used to generate it invokes the assumption 
that sensor behaviour is consistent as a percentage across the BG range, further implying smaller 
absolute errors at lower BG, and higher absolute errors at higher BG. This assumption of sensor 
behaviour is consistent with some studies carried out utilising brands of interstitial CGM devices [98, 
121, 184]. However, other studies report an increase in MARD at lower BG [122, 185]. Further research 
would need to target data in this BG range to develop more a reliable sensor model, if necessary, at 
lower BG. 
 
The linear assumption in the interpolation of BG can also be questioned, as glucose levels could rise or 
fall faster or slower than the expected linear line. This change depends on changes in patient condition, 
as well as any changes in insulin and nutrition inputs, which are not known to us in this dataset. In such 
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conditions, recent work has shown, including times when the input data are better known, that a linear 
assumption is the best in terms of overall error distributions [186-188]. 
 
Another limitation is sensor signal delays. Both the signal filter and the diffusion through the sensor 
membrane will introduce some delay, although it is likely a smaller signal delay of 10-30 seconds. 
However, with the relatively high frequency of sensor measurements the sensor makes (4 times per 
minute) and the relatively long period of times between treatment decisions for which these 
measurements might be used for in a glycaemic control protocol (0.5-3 hours), this combined signal 
delay would not be a hugely significant source of error clinically, and thus was not explicitly accounted 
for in the development of the model. Future work could include an analysis of signal delay to fully 
evaluate this hypothesis and evaluate its effect on performance in glycaemic control. 
 
A further limitation arises from the clinical sensor data. There were only 1312 hours of recorded data 
and the median recording period was 39.4 hours. The data that this model was produced from was also 
the data that this model was tested on, limiting the conclusions of this analyses.  More data, particularly 
from patients that stay for longer than 37.6 hours would allow accurate modelling of long term sensor 
behaviour, particularly if errors change over time in situ, as occurs with interstitial sensors [120, 122, 
145, 189]. Testing the modelled sensor on other sets of data would also help further reinforce this work. 
 
However, it should also be noted that the convergence analysis testing lesser numbers of measurements 
and model accuracy showed that reducing the reference measurements by 42% before creating the 
model did not have not significant effect. In particular, the MARD and Clarke Error Grid results were 
still very close to those of the device in Figures 4.6 and 4.7. Thus, we can also conclude that unless 
specific dynamics are missing from these patients in this dataset, the number of hours used to create 
this model is acceptable in its ability to capture the fundamental dynamics 
 
Finally, the analysis was limited by the amount of patient data from the clinical trial. A larger clinical 
cohort would have allowed more in-depth analysis through cross-validation. In addition, it would enable 
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more precise characterisation of drift ranges and inclusion of larger drifts in the model would not have 
skewed results. However, the results from the MARD, CEG plot, Bland-Altman plot and Trend 
Compass plot indicate that there was enough data to generate a good model that closely captures over 




This chapter has shown a CGM sensor can be characterised from patient clinical data using an auto-
regressive modelling approach. The method presented here has the benefits of explicitly accounting for 
sensor drift and requiring far fewer independently sampled blood glucose measures than other methods. 
Sensor traces can be simulated for BG taken at a clinically realistic rate to create the model. Sensor 
simulations showed modelled sensor behaviour was very similar to the original clinical data, with very 
high similarity in MARD, and equally similar Bland-Altman and Clark Error Grid results further 
validating the model. The novel use of the Trend Compass to validate the trend accuracy reproduction 
within simulation further showed that the model method is able to accurately capture both point 
accuracy and trend accuracy. The overall model method is general to any similar sensor and readily 
extended to interstitial sensors, with or without including interstitial glucose dynamics. It is easily 
simulated on typical clinical data and thus readily able to be incorporated into proven virtual patients to 




Chapter 5 CGM STAR 
5.1 Background  
Continuous glucose monitoring (CGM) technology has improved significantly over the last decade, and 
has become more prevalent in managing diabetes. New generation CGM sensors [93, 107, 117, 121, 
168, 190] with less measurement error than previous iterations [191, 192] have also emerged. These 
CGM sensors have been used in increasing numbers of studies considering them for glycaemic control 
(GC) in the intensive care unit (ICU) [80, 95, 129-131, 136, 140, 172, 193-196]. 
 
The frequent measures available from CGM sensors offer significant opportunity to monitor and 
improve the safety and performance of GC without impacting workload. In particular, they can mitigate 
hypoglycaemia, which can be exacerbated by extended intermittent blood glucose measurement 
intervals [49, 102, 173], and may be an important consideration moving forward in the assessment of 
the merits of glycaemic control in the ICU. 
 
In particular, the hypoglycaemia and variable control that plague many studies often occurs where 
infrequent blood glucose (BG) measurements combine with highly variable changes in patient response 
to care and complex protocols [103, 128, 148, 197]. The increased temporal resolution CGM devices 
provide can monitor real-time BG trends. This monitoring, in turn, allows more rapid treatment 
response to highly dynamic changes in patient condition and glycaemia [24, 32], by modifying insulin 
and/or nutrition delivery to avoid hypoglycaemic excursions, where this variability is well-quantified 
in many cohorts [51-53, 156]. 
 
Both intravascular (IV) and subcutaneous CGM sensors have been used for measurement to guide GC, 
either through use of the CGM sensor readings in a GC protocol [129-131, 136, 140, 172, 193, 194], or 
to observe trends and detect hyper/hypoglycaemia while retaining a GC protocol with intermittent 
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measures [80, 95, 195, 196]. Results have been mixed, with some studies showing good GC results with 
high percentages of measurements in target bands and low numbers of hypoglycaemic incidents [80, 
95, 130, 196]. However, the studies with these positive outcomes tend to be small pilot trials on 
relatively more stable patients [80, 95, 196]. The mixed results can also be attributed to GC performance 
being a product of CGM sensor quality, determined by random error and sensor drift, the interaction of 
the CGM sensor with the specific GC protocol, and the quality of the GC protocol itself. 
 
CGM devices can reduce nursing GC related workload via automation reducing blood sampling 
requirements [128-130]. However, the increased temporal measurement resolution CGM devices 
provide is still somewhat outweighed by the larger point accuracy errors in these devices due to sensor 
drift, bias, and noise [107, 108, 113, 128, 153, 164-166]. Hence, there is significant need to better 
integrate CGM sensor dynamics into GC protocols to maximise their utility. This opportunity is most 
apparent with model based GC and virtual patient driven care [34, 51, 54, 62, 151, 172, 179, 198]. 
 
Interstitial CGM devices have been modelled in the past for testing in virtual environments [107-109, 
113, 128, 153, 182, 199]. However, the previous models have only been used to model CGM 
measurements during closed-loop control of diabetes in the much less dynamic non-critical care 
environment [175]. Only one prior study has completely modelled detailed CGM sensor traces in a 
critical care environment [107]. 
 
This chapter presents the results of using the IV CGM sensor model presented in Chapter 4 to design 
and optimise GC with the established, proven STAR GC protocol [34, 54, 61, 62, 200, 201]. The STAR 
protocol framework is adapted to utilise the increased temporal resolution of a CGM device within a 
typical ICU intervention framework. Clinically validated virtual trials are used to test and optimise this 




Clinically validated virtual trial simulations [149-151] are used to assess the performance, safety and 
nurse workload associated with using CGM sensors to guide GC in a critical care environment. The 
process is summarised in Figure 5.1, where virtual patients are generated from clinical data using the 
ICING (Intensive Care Insulin-Nutrition-Glucose) model [146] and virtual trial simulation is used to 
simulate glycaemic outcomes. In this chapter, virtual trials were performed with a CGM-enabled 
version of the STAR insulin-nutrition protocol and the IV CGM sensor model developed in Chapter 4. 
Multiple cases of CGM-enabled STAR virtual trials were run to determine the best combination of 
safety features using Monte-Carlo simulation. 
 
Figure 5.1: Summary of the virtual patient generation and virtual trial simulation process. 
 
5.2.1 Virtual Patient Generation 
Virtual patients consist of a time-varying insulin sensitivity (SI) profile identified from clinical BG, 
nutrition, and insulin data [202-204]. This process, summarised in the top box of Figure 5.1, has been 
clinically validated on independent data, in clinical use, and in prediction of trial outcomes across 
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multiple cohorts [62, 149, 150, 152]. A virtual trial uses this SI profile to simulate BG outcomes for 
different treatment inputs [54, 62, 205].  
 
5.2.1.1 Clinical Data 
Virtual patients were generated from a clinical data cohort of 236 patients who received insulin therapy 
for more than 24 hours under the STAR protocol [34] from June 2011 to May 2015. Patient 
demographic data is shown in Table 5.1. Additional data and information for these patients can be found 
in Stewart et al. [34]. 
Table 5.1: Patient demographic data for the 236 clinical patients used to generate virtual 
patients. 
STAR Cohort 
Total Patients 236 
Age (Years) 64.5 [53 - 72] 
% Male 67.4% 
Length of Stay (Days) 9.8 [3.9 - 19.2] 
Length of Glycaemic Control (Days) 3.7 [2.0 - 7.1] 
APACHE II Score 21 [17 - 26] 
APACHE II Risk of Death 34.1% [18.4% - 54.9%] 
 
APACHE III Diagnosis: 
Operative Num. Patients % 
   Cardiovascular 35 15 
   Respiratory 5 2 
   Gastrointestinal 10 4 
   Neurological 7 3 
   Trauma 10 4 
   Other (Musculoskeletal, 
renal/genitourinary) 
5 2 
   
Non-operative Num. Patients % 
   Cardiovascular 33 14 
   Respiratory 60 25 
   Gastrointestinal 15 6 
   Neurological 18 8 
   Trauma 17 7 
   Other (Sepsis, metabolic, renal) 21 9 






Model based SI is identified using the clinically-validated ICING metabolic model [146]: 




𝑃(𝑡) + 𝐸𝐺𝑃 − 𝐶𝑁𝑆
𝑉𝐺
 (5.1) 




𝐼(̇𝑡) = −𝑛𝐾𝐼(𝑡) − 𝑛𝐿
𝐼(𝑡)
1 + 𝛼𝐼𝐼(𝑡)
− 𝑛𝐼(𝐼(𝑡) − 𝑄(𝑡)) +
𝑢𝑒𝑥(𝑡)
𝑉𝐼




Where Table 5.2 contains all the variable and parameter definitions and values for the ICING model.  
Table 5.2: ICING model variables and parameter definitions and values. 
ICING model variables 
Blood glucose (G) 
Plasma insulin (I) 
Interstitial insulin (Q) 
Insulin mediated cellular glucose uptake (SI) 
Exogenous glucose appearance from parenteral and enteral sources (P) 
Exogenous insulin (𝑢𝑒𝑥) 
Endogenous insulin (𝑢𝑒𝑛) 
ICING model constant parameters Model values 
Endogenous glucose production (EGP) 1.16 mmol/min or 20.88 mg/dl 
Central nervous system uptake (CNS) 0.3 mmol/min or 5.4 mg/dl 
Non-insulin mediated uptake (𝑝𝐺) 0.006 min
-1 
Kidney insulin clearance (𝑛𝐾) 0.0542 min
-1 
Liver insulin clearance (𝑛𝐿, 𝑥𝐿) 0.1578 min
-1, 0.67 
Insulin diffusion to the interstitial space (𝑛𝐼) 0.0060 min
-1 
Interstitial insulin degradation (𝑛𝐶) 0.0060 min
-1 
Glucose distribution volume (𝑉𝐺) 13.3 L 
Insulin distribution volume (𝑉𝐼) 3.15 L 
 
SI is the only parameter identified on a patient specific basis. It varies hourly with time, and is identified 
from clinical data using integral based fitting [202-204]. It is this time varying SI profile that defines a 
virtual patient. Thus, virtual patients are based off clinical data and clinically observed changes in 




5.2.2 Virtual Trial Simulation 
Virtual trials are carried out using virtual patients, a CGM sensor model, and the STAR protocol. 
Multiple simulation cases are run to optimise the CGM-enabled protocol and performance metrics for 
safety, performance and workload allowed for the evaluation of each simulation case. 
5.2.2.1 CGM Sensor Model 
The IV CGM sensor model is presented in detail in Chapter 4. However, in summary, two main sensor 
errors simulated are sensor drift (Drift) and sensor fluctuations (SensorFlux) via auto-regressive (AR) 
processes. Intermittent clinical BGIM measurements are used as a base from which to simulate CGM 
sensor measurements for use in virtual trials [149, 179-181]. Clinical BG measurements are interpolated 
at half hourly intervals from the last measurement such that: 
𝐵𝐺𝐼𝑀/30 𝑚𝑖𝑛 = 𝑖𝑛𝑡𝑒𝑟𝑝(𝐵𝐺𝐼𝑀)|𝑡=0:30:𝑡𝑒𝑛𝑑 (5.4) 
Drift is applied to each half hourly interpolated BG such that: 
𝐵𝐺𝑏𝑎𝑠𝑒(𝑡=0:30:𝑡𝑒𝑛𝑑) = 𝐵𝐺𝐼𝑀/30 𝑚𝑖𝑛𝑢𝑡𝑒𝑠 ∗ (1 + 𝐷𝑟𝑖𝑓𝑡) (5.5) 
Drift is as described in Chapter 4, where it is defined: 
𝐷𝑟𝑖𝑓𝑡𝑛+1 = 𝛼𝑑 + 𝛽𝑑 ∗ 𝐷𝑟𝑖𝑓𝑡𝑛−1 + 𝛾𝑑 ∗ 𝐷𝑟𝑖𝑓𝑡𝑛 + 𝜉𝑑 (5.6) 
Where 𝛼𝑑, 𝛽𝑑 and 𝛾𝑑 are AR parameters, and 𝜉𝑑  is a random variable. This BGbase is further interpolated 
to provide 4 measurements per minute, the same rate of measurement as the clinical CGM sensor, such 
that: 
𝐵𝐺𝑏𝑎𝑠𝑒/0.25 𝑚𝑖𝑛𝑢𝑡𝑒𝑠 = 𝑖𝑛𝑡𝑒𝑟𝑝(𝐵𝐺𝑏𝑎𝑠𝑒)|𝑡=0:0.25:𝑡𝑒𝑛𝑑 (5.7) 
The simulated sensor output is then defined: 





Where SensorFlux has been defined as in Chapter 4 such that: 
𝑆𝑒𝑛𝑠𝑜𝑟𝐹𝑙𝑢𝑥𝑛+1 = 𝛼𝑠𝑓 + 𝛽𝑠𝑓 ∗ 𝑆𝑒𝑛𝑠𝑜𝑟𝐹𝑙𝑢𝑥𝑛−1 + 𝛾𝑠𝑓 ∗ 𝑆𝑒𝑛𝑠𝑜𝑟𝐹𝑙𝑢𝑥𝑛 + 𝜉𝑠𝑓 (5.9) 
Where 𝛼𝑠𝑓, 𝛽𝑠𝑓 and 𝛾𝑠𝑓 are also AR parameters, and 𝜉𝑠𝑓  is a random variable. 
 
The model parameter values of α, β and γ for both drift and sensor fluctuations are presented in Table 
5.3. The sensor model has been validated against clinical trial data in Chapter 4 and [107]. Equations 
(5.4)-(5.9) thus define the means of generating realistic CGM measures from intermittent clinical BG 
data in virtual trials. 
 





𝜶 𝜷 𝜸 𝝃 median 𝝃 max (absolute) 
1 Drift -0.00147 -0.07152 0.9698 -0.0023 0.2486 
2 Sensor Fluctuations -6.0e-6 -0.261 1.261 -2.66e-06 0.01 
 
5.2.2.2 STAR Protocol 
STAR (Stochastic TARgeted), is a computerised model-based GC protocol utilising stochastic models 
to forecast metabolic variations and glycaemic outcomes for a given insulin and nutrition intervention 
[34, 54, 61, 62]. Future SI values are forecast from current identified SI values using stochastic models 
built from cohort data [52, 146]. These forecast SI values can be used to generate probable BG outcome 
distributions for any given insulin and nutrition intervention. STAR overlaps this distribution of 
potential BG outcomes with the clinically targeted 4.4 – 8.0 mmol/L range, using the 5th percentile of 
likely BG outcomes to ensure a 5% maximum risk of BG < 4.4 mmol/L. Insulin and nutrition treatments 
are selected to meet this goal, with a secondary goal of maximising nutrition. The stochastic model and 
corresponding SI and BG forecasts used to determine these insulin and nutrition treatments are shown 




Figure 5.2: Stochastic model shows the current SI plotted against the percentage likelihood of 
future SI. The stochastic model is used to determine the SI forecast and corresponding BG 
forecast. 
 
In clinical use, BG is measured 1-hourly outside the 4.4 – 8.0 mmol/L range, and STAR offers 2 and 3 
hour options for patients in the target range. In simulation, the maximum available measurement interval 
is always chosen. However, clinically it is left to staff discretion, resulting in slightly higher, voluntarily 
chosen measurement rates in some units [34]. 
 
5.2.2.3 CGM-enabled STAR 
The CGM sensor model of Equations (5.4)-(5.9) is used to replace intermittent 1-3 hourly BG 
measurements in STAR. To simulate automation with the CGM sensor, interventions are calculated 
hourly using the modelled CGM sensor glucose (SG) value, unless a recalibration measure is taken, in 
which case this recalibration value is used instead. A typical clinical workload revolves around 
interventions at 1-3 hourly intervals, and so hourly CGM measures reduces required blood draws and 
thus clinical workload, while potentially improving control with more frequent adjustment. Hourly GC 
control can be very tight and automated CGM measures enable this approach for clinical practice, where 




CGM recalibrations reset SG to the calibration BG value assuming a point-to-point match [107]. 
Recalibrations are triggered when any of: (1) a specified glucose guard rail is crossed; (2) there is a 
rapid change in CGM measured blood glucose; or (3) 8 hours has passed since the last recalibration 
[93]. There is thus a minimum possible workload of 3 measures per day, unless conditions (1)-(2) are 
triggered. 
 
Guard-rails based on CGM measures are used to trigger calibration measurements ensuring higher 
sensor accuracy at areas of higher risk. Pairs of guardrail values were used, comprised of upper and 
lower BG thresholds for recalibration. Guard-rails of (4.0 mmol/L, 8.0 mmol/L) and (4.4 mmol/L, 8.0 
mmol/L) were tried, defining the intermediate BG range between hypo- and hyperglycaemia [25, 26, 
65]. Any single SG measurement outside this range triggered a recalibration measure, as well as a STAR 
insulin-nutrition intervention change based on the recalibration blood glucose measurement. 
 
A rolling window monitoring changes in SG is also used to trigger recalibration measures. The rolling 
window looks at the change in SG measurement over a specified time frame, and this window rolls 
forward as more SG measures are available. If the magnitude of change in SG over this window 
exceeded a specified threshold, a recalibration is triggered and a treatment recommended using the 
recalibration measure. Sensitivity of GC performance to the interval and magnitude of SG change in 
these rolling windows was evaluated. Rolling window intervals of 20, 30, and 40 minutes were tested, 
as well as absolute changes in BG of 0.5, 1.0 and 1.5 mmol/L over these intervals. The minimum time 
allowed between consecutive recalibrations was set to 1 hour to avoid excessive increases in workload 
that would not significantly affect sensor performance. 
 
In the Christchurch Hospital ICU, insulin therapy is delivered as boluses every 1-3 hours. In this study, 
insulin was administered via insulin infusions, a delivery method more commonly used elsewhere, and 
easier to administer in an automated ‘closed loop’ manner. In an automated closed loop, full automation 
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would not require a nurse to be present to program boluses or infusions, thus further lowering clinical 
workload. This study examines the impact of CGM sensors on safety and performance, as a step towards 
further or complete automation. 
 
5.2.2.4 Virtual Trials Analysis 
A simulation of clinical STAR, in which BG is measured intermittently every 1-3 hours and insulin is 
delivered in the form of boluses (Case B), was run to compare to the clinical STAR data (Case A), to 
show the difference between clinical and virtual patients in addition to the impact of always choosing 
the longest measurement intervals. STAR with 1 hour BG measurements and insulin infusions (Case 
C) was simulated to provide a baseline for comparison, where the impractical measurement rate of 24 
BG measurements per day represents an upper bound of what performance might be expected with a 
CGM device measuring hourly. Table 5.4 lists all virtual trials utilising the IV CGM model. Three 
Monte-Carlo simulations are carried out per virtual trial in Table 4, bringing the total number of virtual 
patient sensor trace outputs to 708 for each virtual trial. In particular, because the CGM model has a 
random component, no two or more runs of a given virtual patient have the same CGM trace. Multiple 
runs and many patients alleviates any issue of outlier behaviour affecting results. 
 
Cases 1 and 2 were run to optimise the BG levels of the guard rails for GC performance, safety and 
workload. Case 3 repeats Case 1, but allows for intervention interval length to extend up to 3 hours to 
assess this parameter in a semi-automated case where changing interventions hourly has a workload 
cost. A total of 9 simulations (Cases 4-12) were carried out to evaluate the effect of changing the 
parameters of the rolling window. Finally, recalibration periods were varied from 6-12 hours (Cases 





Table 5.4: List of simulation cases run using CGM sensor model. 





Window Length (t) 
(Minutes) 
ΔBG with BG between 
guardrails (4.4 and 8.0 
mmol/L) 
1 4.0 and 8.0 8 - - 
2 4.4 and 8.0 8 - - 
3 (1-3 hour 
interventions) 
4.0 and 8.0 8 - - 
4 4.4 and 8.0 8 40 ±1.0 mmol/L 
5 4.4 and 8.0 8 30  ±1.0 mmol/L 
6 4.4 and 8.0 8 20 ±1.0 mmol/L 
7 4.4 and 8.0 8 40 ±0.5 mmol/L 
8 4.4 and 8.0 8 30 ±0.5 mmol/L 
9 4.4 and 8.0 8 20 ±0.5 mmol/L 
10 4.4 and 8.0 8 40 ±1.5 mmol/L 
11 4.4 and 8.0 8 30 ±1.5 mmol/L 
12 4.4 and 8.0 8 20 ±1.5 mmol/L 
13 4.0 and 8.0 6 - - 
14 4.0 and 8.0 12 - - 
 
5.2.2.5 Performance Metrics 
Hourly resampled measurements are used so direct comparisons can be made between cohorts with 
different measurement and intervention intervals. For each virtual trial, the following performance 
indicators are used: 
• Safety was measured as the percentage of patients who had a severe hypoglycaemic episode 
(BG < 2.22 mmol/L), as well as the percentage of resampled BG < 4.0 mmol/L. 
• Performance was measured as the percentage of hourly resampled measurements in the 4.4 
– 7.0 mmol/L and the 4.4 – 8.0 mmol/L target bands [25, 26, 65]. 
• Workload was measured by the number of manual blood glucose measures per day. 
 
Each virtual trial in which the CGM sensor is employed also recorded the SG results, with added sensor 
errors, alongside the true (simulated) BG results to evaluate the impact on performance in true BG 
against what would be seen as ‘true’ in a clinical setting where only SG would be known. Thus, all of 
the performance metrics are measured using true BG to reflect the actual results of each trial, while SG 
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results are provided to evaluate how the results would have been reported clinically based off observed 
CGM data including errors. This comparison shows the impact of any sensor errors on perceived versus 
true performance, which is only possible in virtual trials and may be significant in sensors with larger 
errors and/or drift. 
 
5.3 Results 
5.3.1 Virtual Trials Results 
Table 5.5 presents baseline clinical (Case A) and virtual trial results for STAR without CGM devices 
(Case B). The clinical and simulation results are broadly similar, with discrepancies due to the 
difference in measurement interval, where clinical staff are free to select 1-3 hours between 
measurements [61, 62], but in simulation the maximum available is selected. As a result, the main 
difference between the results was the simulated clinical STAR had a higher percentage of BG 
measurements in the 4.4 – 7.0 mmol/L band (76.9% vs 62.8%), but a more similar number in the 4.4 – 
8.0 mmol/L range (89.0% vs 83.7%). Similarly, the incidence of mild hypoglycaemia was slightly 
increased in simulation (0.5% vs 1.1% BG < 4.0 mmol/L), while the percentage of patients who 
experienced a severe hypoglycaemic event (BG < 2.22 mmol/L) were similar and low (1.27 vs 0.85% 
for simulated and clinical respectively). Thus, Case A and Case B are not drastically different, especially 
in per-patient results, to say the virtual cohort is a good representation of the clinical cohort. 
 
The last column in Table 5.5 shows Case C, the best case STAR controller results using 1 hour 
interventions and insulin infusions. GC performance was slightly improved compared to simulated 
clinical STAR in Case B (80.0% vs 76.9% in the 4.4 – 7.0 mmol/L range, 89.1% vs 89.0% in the 4.4 – 
8.0 mmol/L range), while workload was significantly increased (24 interventions per day vs 12.2 in the 
clinical STAR simulation), as expected. This result is the baseline best case for comparing CGM-





Table 5.5: Clinical STAR results, simulated clinical results and simulated 1 hour STAR 
infusions. 
 Clinical 1-3 Hr STAR Bolus 
(Case A) 
Simulated Clinical 1-3 
Hr STAR Bolus (Case B) 
Simulation 1 Hr STAR 
Infusions (Case C) 
Whole Cohort Statistics 
Number of patients 236 236 236 
No. BG Measures 11001 10622 20972 
No. interventions per day 12.7 12.2 24 
Percentage of patients who had at least 
one measurement < 2.22 mmol/L (No. 
of patients) 
0.85 (2) 1.27 (3) 0.85 (2) 
Hourly Resampled Statistics 
% BG within 4.4 - 7.0 mmol/L 62.8 76.9 80.0 
% BG within 4.4 - 8.0 mmol/L 83.7 89.0 89.1 
% BG within 8.0 - 10 mmol/L 11.4 6.6 6.2 
% BG < 5.0 mmol/L 4.4 8.6 13.1 
% BG < 4.0 mmol/L 0.51 1.08 1.05 
Median BG [IQR] (mmol/L): 6.6 [6.0 – 7.4] 6.1 [5.6 – 6.8] 5.8 [5.3 – 6.6] 
Median insulin dose [IQR] (units/hour): 2.5 [2.0 - 3.5] 3.0 [2.0 - 4.5] 4.0 [2.0 - 6.0] 
Per-patient median dextrose rate for 
those fed [IQR] (g/hour): 
5.5 [4.4 - 6.7] 5.8 [4.5 - 6.7] 5.9 [4.7 - 6.7] 
 
Table 5.6 presents virtual trial results for Cases 1-4 in Table 4. Each virtual trial presents results in terms 
of ‘true’ underlying BG and observed SG in two columns. Performance and safety for all trials in Table 
5.6 are broadly similar to the baseline results for Case C in the last column of Table 5.5, but with 
significantly reduced workload. 
 
In Table 5.6, the number of recalibration, and thus manual BG, measurements per day ranged from 3.0-
3.6 per day. The percentage of true BG measurements within the 4.4 – 7.0 mmol/L band ranged from 
71.6% to 77.1%, while the percentage of true BG measurements within the 4.4 – 8.0 mmol/L band 
ranged from 87.0% to 88.1%. The percentage of true BG < 4.0 mmol/L ranged from 1.30% to 1.37%. 
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Additionally, the percentage of patients who experienced a hypoglycaemic episode ranged from 0.71% 
(5 of 708 patients) to 1.41% (10 of 708 patients). The last column of Table 5.6 presents the results 
typical of the virtual trials in which a guard rail and a rolling window were employed.  
 
All of the different rolling window definitions (Cases 4 - 12) had very similar virtual trial results, so 
only one set of full results is shown for brevity in Table 5.6. Figure 5.3 shows the similarity in these 9 
results, with the number of recalibrations per day ranging from 3.5-4.1, percentage BG within 4.4 – 7.0 
mmol/L band ranging from 76.9 – 77.3%, percentage BG within 4.4 – 8.0 mmol/L band ranging from 
87.9 – 88.1%, and percentage BG < 4.0 mmol/L band ranging from 1.25 – 1.33%. 
 
Figure 5.4 shows the virtual trials testing recalibration period (Cases 13-14) for robustness and 
optimisation. Figure 5.4(a) shows the percentage of BG measurements within the thresholds, and shows 
no change in percentage BG in band as reported by the sensor and no change in median BG (Table 5.7). 
Figure 5.4(b) compares the percentage of BG measurements less than the hypoglycaemic thresholds of 
2.22 mmol/L and 4.0 mmol/L between the recalibration periods, while Figure 5.4(c) compares the nurse 
workload and patient safety. Small degradations in performance and safety are observed versus larger 
reductions in workload, defining a clear trade-off for clinicians. 
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Table 5.6: Results from virtual trials utilising guard-rails, with one representative utilisation of the rolling window. 
 Case 1: Guard Rail 4.0-8.0 mmol/L, 
minimum 8 Hr Recalibration, Hourly 
Interventions 
Case 2: Guard Rail 4.4-8.0 mmol/L, 
minimum 8 Hr Recalibration, Hourly 
Interventions 
Case 3: Guard Rail 4.0-8.0 mmol/L,  
Minimum 8 Hr Recalibration, 
1-3Hr Interventions  
Case 4: 40 min rolling window, ΔBG 
of -1.0 mmol/L with BG < 4.4 
mmol/L, ΔBG of  +1.0 mmol/L with 
BG > 8.0 mmol/L, Hourly 
Interventions 
Whole Cohort Statistics 
 True BG SG True BG SG True BG SG True BG SG 
Number of patients 708 708 708 708 
Total hours 62520 62566 62892 62553 
No. recalibrations 8603 9186 7944 9359 
No. recalibrations per day 3.3 3.5 3.0 3.6 
Percentage of patients who had at 
least one measurement < 2.22 
mmol/L (No. of patients) 
1.13 (8) 1.27 (9) 1.41 (10) 1.41 (10) 0.71 (5) 1.13 (8) 1.41 (10) 2.26 (16) 
Hourly Resampled Statistics 
% BG within 4.4 - 7.0 mmol/L 76.6 77.4 77.1 78.2 71.6 73.2 76.9 78.6 
% BG within 4.4 - 8.0 mmol/L 87.9 88.4 88.1 89.0 87.0 87.2 88.0 89.1 
% BG within 8.0 - 10 mmol/L 6.5 5.5 6.4 5.6 7.7 6.9 6.4 5.5 
% BG < 5.0 mmol/L 13.3 16.0 13.5 14.8 10.1 11.6 13.8 15.1 
% BG < 4.0 mmol/L 1.37 1.31 1.30 1.49 1.37 1.48 1.30 1.56 
% BG < 2.22 mmol/L 0.019 0.024 0.017 0.022 0.014 0.016 0.021 0.027 
Median BG [IQR] (mmol/L): 6.0 [5.4 - 6.8] 5.9 [5.3 - 6.7] 6.0 [5.4 - 6.7] 5.9 [5.3 - 6.69] 6.3 [5.6 - 7.0] 6.2 [5.5 - 6.9] 6.0 [5.4 - 6.7] 5.9 [5.3 - 6.7] 
Median insulin dose [IQR] 
(units/hour): 
4.0 [1.5 - 8.0] 4.0 [1.5 - 8.0] 3.5 [1.7 - 5.6] 4.0 [1.5 - 8.0] 
Per-patient median dextrose 
rate for those fed [IQR] 
(g/hour): 




5.5 [4.5 - 6.6] 
 
5.2 [4.1 - 6.1] 5.5 [4.7 - 6.6] 
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Rolling window parameter testing 
 
(a) Comparing the percentage of BG in band for each of the rolling window lengths. 
 
(b) Comparing the percentage of BG less than the threshold for each of the rolling window lengths. 
 
(c) Comparing rolling window length with nurse workload. 
Figure 5.3: Graphical results from varying the parameters of the rolling window, with a guard 




Recalibration robustness trials 
 
(a) Comparing the percentage of BG in band for each of the recalibration periods. ‘Real’ BG is 
shown with solid lines, SG is shown with dotted lines. 
 
(b) Comparing the percentage of BG less than the thresholds for each of the recalibration periods. 
Again, ‘real’ BG is shown with solid lines, SG is shown with dotted lines. 
 
(c) Comparing recalibration period with nurse workload and patient safety. 
Figure 5.4: Graphical results from the testing of varying recalibration period with a guard rail 















(resampled) BG SG 
6 (Case 13) 6.0 [5.4 - 6.7] 5.9 [5.3 - 6.7] 4.0 [1.5 - 8.0] 5.5 [4.6 - 6.6] 
8 (Case 1) 6.0 [5.4 - 6.8] 5.9 [5.3 - 6.7] 4.0 [1.5 - 8.0] 5.5 [4.6 - 6.6] 
12 (Case 14) 6.0 [5.4 - 6.8] 5.9 [5.3 - 6.9] 4.0 [1.5 - 8.0] 5.6 [4.6 - 6.6] 
 
5.4 Discussion 
5.4.1 Sensor Use in Simulated GC 
In general, replacing the more accurate intermittent BG measurements of STAR with CGM sensor 
measurements significantly reduced workload with clinically small to negligible effects on performance 
and safety. This trade-off is what clinicians must consider before fully implementing CGM sensors in 
GC. It is based on the underlying sensor drift, bias and error of this CGM [107], where lower errors and 
drift might improve these results if found via a different or improved sensor. 
 
For Case 1, the number of measurements required per day was 3.3, including recalibrations, an 
improvement in workload of 74% compared to the 12.7 for the clinical STAR Case A, and 73% for its 
virtual trial Case B. Utilising CGM sensor measurements resulted in similar performance to simulated 
STAR, Case B, (76.6% vs 76.9% in the 4.4 – 7.0 mmol/L range) with only a slight increase in the 
percentage of BG < 4.0 mmol/L (1.4% vs 1.1%) for the simulation (Table 5). Results were not different 
if the lower guard rail was increased to 4.4 mmol/L (Case 2). Hence, the trade-off between workload, 
and clinical performance and safety, is clear in that a major reduction in BG measurements is achieved 
while safety and GC performance are maintained. The 4.4 mmol/L guard rail is also a better choice as 




If the time between new interventions was allowed to vary up to 3 hours (Case 3) a treatment interval 
similar to that clinically observed (Table 5.5) is achieved, except that now most treatments are 
calculated from the CGM SG measurement. This trial shows the potential results of the integration of a 
CGM device into the STAR protocol without any further changes to the controller that currently utilises 
intermittent BG measurements in the same interval. It thus matches current intervention workload if 
there is no automation. The key metrics were all similar to the first sensor model virtual trial with 1 
hour infusions (3.0 recalibrations per day vs 3.3, 87.0% BG measurements in the 4.4 – 8.0 mmol/L band 
vs 87.9%, 1.37% BG measurements < 4.0 mmol/L vs 1.37%, 0.014% BG measurements < 2.22 mmol/L 
vs 0.019%). This result suggests STAR can be safely used with the GlySure CGM SG measures, or any 
similar performing CGM sensor, without requiring hourly treatment updates, thus limiting or reducing 
the level of automation required, while significantly reducing workload. 
 
Case 4 was not significantly different to Cases 1-3, and thus the added rolling window did not show 
any notable benefit in most of the key performance metrics. Safety was maintained, reflected in the 
percentage of patients who experienced a severe hypoglycaemic event (1.41% (10 patients of 708) vs 
1.13% (8 of 708) for Case 1). Thus, rolling windows to capture rapid change impact safety relatively 
independent of performance and workload. 
 
Figure 5.4(a) shows the percentage of BG measurements within the thresholds, and shows no change 
in percentage BG in band as reported by the sensor and no change in median BG (Table 5.7) for a given 
change in recalibration period. However, there is a decrease of percentage BG in band for the true BG 
as the recalibration period is increased. This outcome reflects the decreased accuracy of the CGM sensor 
as the sensor is allowed to operate for longer without recalibration, and particularly, the unseen impact 




Figure 5.4(b) shows no change in the incidence of severe hypoglycaemia as reported by the true BG or 
SG. Again, there is a slight disparity between true BG and SG, where the true BG has the incidence of 
mild hypoglycaemia increasing at a slightly higher rate. This disparity again reflects the decreased 
accuracy of the CGM sensor and unseen impact of sensor drift with longer recalibration intervals. 
Overall, results are robust to calibration interval with mild degradation over longer periods, as expected. 
Results are not worse, in these cases, due to the use of guard rails to prevent BG levels from “escaping” 
the desired range and “forcing” recalibration if required. Thus, it is only unseen drift when true BG 
moves but drifting SG remains in band that is an issue. 
 
Figure 5.4(c) shows the inverse relationship between nurse workload and patient safety. A 6 hour period 
between recalibrations increased the number of recalibrations per day to 4.3, which is still a large 
reduction from current clinical workload, but did not significantly increase the performance or safety 
of the controller. As expected, there was a slight increase in BG < 2.22 mmol/L with increased time (12 
hours) between recalibration measures. Overall, a maximum of 8 hours between recalibrations appears 
to be an appropriate balance of workload and safety with this level of sensor performance. 
 
Surprisingly, the addition of a rolling window monitoring the rate of change of BG did not affect overall 
performance. This result could be due to the activation condition for the rolling window being in 
practice very similar to the condition for which the guard-rails activated a recalibration and intervention. 
The rolling window recalibration and intervention would activate earlier than the guard rail, and thus 
there would be no need for another recalibration if or when BG reached 4.4 mmol/L or 8.0 mmol/L if 
it occurred within an hour of the rolling window recalibration. Thus, the benefit of the rolling window 
is in capturing guard rail events earlier to improve safety. 
 
Both subcutaneous and venous/arterial CGM devices have been studied for use in the ICU [79, 80, 95, 
129-131, 136, 140, 172, 193-196]. Of these studies, Boom et al. [130] offers the most comparable study 
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to the one presented, where GC based on a sliding scale algorithm was guided by subcutaneous CGM 
measurements. Performance, as measured by the percentage of measurements in the target range, was 
worse (69% in the 5.0 – 9.0 mmol/L target range vs. 88.0% in the 4.4 – 8.0 mmol/L target range for 
Case 4 of CGM-enabled STAR) [130]. Safety was comparable between the two studies, with no 
incidences of severe hypoglycaemia (<2.22 mmol/L) in Boom et al. (0 out of 78 patients) compared to 
1.41% of patients (10 out of 708 patients) in Case 4 of CGM-enabled STAR. Other studies in which 
GC was guided by subcutaneous CGM sensors reported average GC performance results alongside 
significant incidences of hypoglycaemia [79, 172], while another reported reduced incidences of 
hypoglycaemia but no improvement in GC performance compared with intermittent BG measures 
[129]. 
 
Other studies show a similar percentage time in target range, but are less comparable because they used 
blood gas analysers to measure BG and guide GC. In particular, several small studies show relatively 
high percentage of BG measurements in a tight range, with 0, or close to 0, incidence of severe 
hypoglycaemic events (BG < 2.22 mmol/L) [80, 95, 196]. Other studies have used blinded CGMs to 
assess CGM point and trend accuracy, through MARD and Clarke error grid analysis, or detect hypo- 
or hyper-glycaemic events that may not be measured with intermittent BG measurements, but were not 
used to guide GC [96, 115, 117, 168, 206]. Overall, this study uses clinical data from a large number of 
ICU patients to demonstrate the potential for using CGMs to aid or guide GC in the ICU, an outcome 
supported by preliminary results from previous studies. 
 
The overall results of this study show replacement of intermittent BG measurements in GC may 
significantly reduce nurse workload, without compromising GC safety or performance. The simulated 
CGM sensor was able to decrease nurse workload, in the form of manual measurements, from 12.7 
measures per day to 3.0-3.6 measures per day, depending on which guard rail or rolling window 
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definition is employed. This decrease in nurse workload is achievable, with no significant changes to 
control performance or patient safety. 
 
This result is in line with expectations [173], which hold that more frequent measurement would aid 
control. Additionally, STAR already had a high level of performance [34]. Lesser performing GC 
protocols could see improvements not evident in this study. 
 
5.4.2 Limitations 
One of the limitations of this study was that in the making of the CGM sensor model, the clinical data 
used to construct the model had a very low number of BG measurements less than 5.0 mmol/L [107]. 
This limitation makes it harder to predict sensor behaviour at this lower BG region, and it was assumed 
that the sensor behaviour had consistent percentage error for the range of BG measured, implying 
smaller absolute errors at lower BG and higher absolute errors at higher BG. This assumption is 
consistent with other studies carried out using brands of interstitial CGM devices [98, 121, 184], while 
others report an increase in MARD at lower BG [114, 122, 185]. This limitation could have a sizeable 
effect on the data produced, as the percentage of BG measurements < 5.0 mmol/L recorded by the 
sensor ranged from between 10.1% to 13.8% for the sensor model virtual trials. Further research would 
need to target data in this BG range to ensure the reliability of the sensor model at lower BG. However, 
based on the initial validation the current model is likely acceptable. Similarly, if the model of the CGM 
sensor at lower BG is inaccurate, a rolling window in a clinical setting could prove more effective in 
catching rapid declines in patient condition and BG than the simulations suggest. 
 
A further limitation is sensor signal delays. Both the signal filter and the diffusion through the sensor 
membrane will introduce some delay. However, with the relatively high frequency of sensor 
measurements (4 times per minute) and the relatively long period of time between treatment decisions 
for the STAR protocol (1-3 hours), this combined signal delay would not be a hugely significant source 
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of error clinically. Thus, it was not explicitly accounted for in the development of the model or the 
simulation of the CGM sensor traces. 
 
5.5 Summary 
A previously validated model of an IV CGM sensor was used in place of intermittent BG measurements 
to guide GC decisions under the STAR protocol in a virtual environment. Virtual trials are used to 
evaluate the impact on safety, performance, and workload of implementing these or similar CGM 
sensors for GC using the STAR protocol. Using a range of guard rails and/or rolling windows delineated 
trade-offs found in using CGM sensors, and decreased the number of required blood draws for BG 
measures by up to 73%, while also maintaining GC performance and patient safety. Performance and 
safety were robust to reasonable changes in sensor recalibration period, as well as to changes in rolling 
window parameters of window length and BG change. Overall, the use of a typical CGM sensor in 
clinically validated virtual trials shows the potential to reduce clinical workload significantly. The lack 
of equally significant improvements in performance are likely due to the already very good and 




Chapter 6 Variability and Level Analysis of CGM Sensor Traces 
6.1 Background 
A recent study of metabolic variability and mortality outcomes showed no difference in underlying 
metabolic variability between survivors and non-survivors [32], suggesting patient outcomes are a 
function of the quality of control delivered and not patient-specific or cohort-specific characteristics. 
Poorly delivered control might thus affect study outcomes when looking for benefit or harm, as studies 
show good glycaemic control (GC) may need to be achieved for essentially all patients to achieve 
mortality reduction [48]. As such, there is a clear need for safe, effective control algorithms able to 
directly manage the significant intra- and inter- patient variability that makes GC difficult [49, 148, 
207]. This outcome points to a clear need for greater input from the fields of control systems and 
automation to manage variability and provide control. 
 
Model based methods have been developed to achieve this goal [34, 41, 54-56]. In particular, many 
monitor and respond to changes in patient-specific metabolic condition using an insulin sensitivity 
model parameter. Insulin sensitivity is a key determinant of the glucose uptake response to an insulin 
dose, and this sensitivity is most variable early in the intensive care unit (ICU) stay where most 
hypoglycaemia occurs [23], both in response to patient condition and clinical interventions [24, 57-59, 
208].  
 
However, while the future looks optimistic for model-based GC and patient outcomes [44], there is still 
much debate over what GC targets are appropriate and/or safe for an ICU context [39]. Many prefer 
higher targets out of fear of hypoglycaemia [26-29]. Some studies have shown greater benefit from 
lower targets [25, 26, 40, 64, 65]. Further, evidence suggests these targets may be patient specific and/or 
differ between ICU cohorts [66]. Confounding this issue is a lack of consensus on how to measure 
and/or report GC outcomes and variability at a cohort and patient level [30, 67], especially as some 
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model-based GC use variability [52, 53, 156, 157] to dose insulin [54, 156-158]. 
 
Thus, there is a clear need for coherency and novelty in regard to assessing glycaemia, both in level and 
variability, preferably in a fashion readily transferred to other clinical signals. Consensus in assessing 
state or level and variability with metrics well-correlated with clinically relevant outcomes would 
provide the means to assess all protocols and methods, where such metrics are lacking [30, 50]. Hence, 
while automation and control are emerging in this field, the key control parameter, the measure of 
desirable outcome parameters, glycaemia and its variability in this case, are missing or not well-defined. 
 
This chapter summarises the state of the art with regards to assessing glycaemic level and variability in 
hospital ICU cohorts. It explores the common definitions, and their advantages or disadvantages. It then 
provides a vision for the future through a new, novel, state-based description of these quantities, in an 
attempt to better capture patient and cohort glycaemic behaviour. It is particularly applicable given the 
rise of CGM use in general, and in the ICU in particular [174, 209, 210]. The methods, review, outcomes 
and analyses are generalisable to a range of clinical metrics in critical care. 
 
6.2 State and Variability: Measures of Metabolic Quantities 
6.2.1 State and Level of Blood Glucose 
Blood glucose (BG) concentration, or its average across a population or time period or both, is the most 
common metric reported. Assumptions around appropriate concentrations and how they should be 
achieved underpin much of the glycaemic control research and clinical practice. Common thresholds 
for blood glucose and dysglycaemia differ in derivation and definition between different intensive care 





Adult hyperglycaemia is well researched and BG greater than 8.0 mmol/L is the typical threshold 
defining hyperglycaemia [2, 35, 36, 54, 211-213]. This definition and the upper limit on GC target 
ranges varies within the literature from 6.1 – 9.0 mmol/L, where many individual clinicians, centres, 
and protocols define their own safety thresholds for normoglycaemia. One meta-analysis showed no 
particular advantage for GC ranges, although they found lower ranges were associated with higher 
incidence of hypoglycaemia [214]. However, several other studies have shown lower ranges, while 
avoiding hypoglycaemia, offer reduced risk of death [25, 26, 65]. These differing outcomes, using 
different ranges, are a confounding factor in the pursuit of both consensus and reduced clinical 
hyperglycaemia. 
 
Thresholds for mild and severe hypoglycaemia in adults are also well defined [23, 28, 29, 54, 102, 215, 
216]. The consensus is mild hypoglycaemia occurs at 4.0 – 4.4 mmol/L, while severe hypoglycaemia 
is most commonly defined as BG < 2.2 mmol/L [2, 130]. These thresholds result from clinical studies 
of decreased BG and the onset of physiological responses as a result of hypoglycaemia [217], and they 
may be patient-specific [218]. In particular, patients with type 2 diabetes and persistent hyperglycaemia 
can exhibit hypoglycaemic like symptoms at normal BG levels [218]. 
 
6.2.1.2 Neonates 
In contrast to the well reported clear limits of normoglycaemia for adults, normoglycaemia for infants 
is less intensively examined and defined. As a result, clinical practice and research definitions differ. 
Alsweiler et al. [219] surveyed 27 tertiary neonatal units in Australasia for their definition and 
management of hyperglycaemia in very low birthweight infants. Variance in the clinical definitions of 
hyperglycaemia from these specific neonatal units ranged from 7.0 – 15.0 mmol/L, though most used 




Alsweiler et al. also observed large variance in target ranges for subsequent insulin therapy, though 
many defaulted to the normal ranges for adult glycaemia of 4.0 – 8.0 mmol/L. In some cases, the upper 
target ranged between 8.0 – 10.0 mmol/L. Some of the lower ends of these target ranges were much 
lower at 2.5-3.0 mmol/L, reflecting evidence of a possible tolerance for lower BG by infants [220, 221]. 
Thus there is overall little consensus for onset criteria and targets in neonatal GC, reducing effectiveness 
of protocols, particularly with respect to later outcomes, and ability to compare study outcomes. 
 
In contrast to adult definitions, and also to the clinical thresholds observed by Alsweiler et al., the 
thresholds for neonatal hyperglycaemia used in literature by researchers is significantly lower, from 
6.9-8.3 mmol/L [222-226]. They are based on observed distributions of BG in preterm infants [227], 
where less common extremes are used to define abnormal BG. However, these statistical definitions 
may simply describe measured BG in this cohort, rather than what may be clinically desirable, 
beneficial, or obtainable via GC [227]. 
 
Neonatal hypoglycaemia is controversial, where agreement has not been reached on either thresholds 
or treatment [220, 228-230], in part because it is often asymptomatic. Some studies show neonatal BG 
concentrations reach natural lows at approximately 2 hours after birth [231], while others fail to observe 
this nadir [232, 233]. Infants experiencing hypoglycaemia may also be asymptomatic [234-237], unlike 
adults, and it is still unknown if asymptomatic hypoglycaemia is the same as symptomatic 
hypoglycaemia, or if such thresholds are patient-specific. However, neonatal hypoglycaemia (defined 
as <2.6 mmol/L) has been linked with poor neurologic outcomes in later life [221], and thus better 
definition in this area would lead to improved treatments and outcomes. 
 
6.2.2 Measures of Glycaemic Variability 
Though perhaps intuitive qualitatively, glycaemic variability is difficult to effectively quantify. Many 
reviews have undertaken to summarise variously measures of glycaemic variability, particularly in the 
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context of Diabetes management, and more fully describe their advantages and limitations [75-78]. 
Many metrics, and adaptations of metrics, exist, but in general most fall into the following broad 
categories: 1) descriptors of middle and range; 2) descriptors of total or summed variability or excursion 
length; and 3) descriptors of time in range. 
 
 The most standard methods for describing and quantifying glycaemic variability are statistical 
descriptors of middle and range in data. The most common descriptor of variability is to report the 
standard deviation (SD) of BG measurements alongside the mean BG value [79]. Similarly, the IQR 
(inter-quartile range) is a non-parametric alternative, reported alongside median BG. These metrics are 
popular because of their ease of use [75]. However, the SD is a measure of dispersion, rather than 
variability, and is limited in its ability to reflect the time course of BG measurements [80]. 
 
The limitations of the SD for describing glycaemic variability are shown in Figure 6.1, where the mean 
and SD are the same for two time courses of intermittent BG measurements. In this case, the same set 
of BG measurements is arranged in two different patterns, one a decrease at a constant rate, and the 
other moves between extremes. Because both have exactly the same measurement set, both have the 
same mean and SD. If glycaemic variability is more truly a function of the change in BG, with more 
rapid changes exerting different physiological effects than slower changes, than patient outcomes could 
differ in these two cases. Thus, the SD is extremely limited in its ability to describe the time course of 
glycaemic variability. 
 
In addition, the mean and SD assume a normal distribution, which is inaccurate, particularly in 
dysglycaemia, as BG is usually highly lognormal and skewed. Thus, this measure for variability may 
be inappropriate to use, particularly if there are a large number of measurements near the hypoglycaemic 
or hyperglycaemic ranges of BG. Equally, all such measures requiring a normal distribution assumption 




Figure 6.1: Two sensor traces with accompanying intermittent BG measures. The intermittent 
BG measures are the same between the two data sets, and so have the same mean and standard 
deviations, but display differing behaviours. 
 
The Coefficient of Variability (CoV), which is the mean divided by the standard deviation, is for some 
a preferred, more intuitive, measure of glycaemic variability [75]. CoV can be a good measure of overall 
glycaemic variability, as research has shown that aiming for a CoV lower than a certain threshold (36%) 
allows for the distinction between stable and unstable glycaemia [81, 82].  However, this metric suffers 
the same limitations as discussed regarding the mean and SD above. For the data in Figure 6.2, the CoV 
would by definition be the same between these two patients.  
 
Metrics examining total glucose excursion include Area under the BG curve (AUC) and Glucose Miles. 
AUC or area around a line is common in diabetes and non-critically ill cohort studies, often with more 
frequent continuous glucose monitoring (CGM) [83-85]. Two zig-zagging sensor traces could 
theoretically have the same area, even though one trace is rising in level, while the other is falling. This 
behaviour would suggest the two traces have the same level of variability, but with differing behaviours, 
indicating how AUC is an overall measure of variance, but not specific to time course.  This issue is 




Figure 6.2: Two sensor traces with very similar AUC, but differing behaviours. 
 
Glucose Miles is another way to measure variability, measuring the total ‘distance’ travelled by 
movements in BG through intermittent BG or CGM traces. It is embedded as part of some other 
measures [86, 87]. However, two traces can have the same Glucose Miles with very different mean BG, 
as shown in Figure 6.3 for a bias, and Figure 6.2 where the median is the same. Thus, this metric is 
similar to AUC in giving a total, but is not specific or reflective of the time-varying behaviour of blood 
glucose. 
 
Furthermore, while Glucose Miles and AUC can be useful descriptors of cohort variability when paired 
with measurements of mean or median BG, both have an inability to describe variation away from some 
longer term average or glycaemic state, which may be important to recognise clinically. Similar metrics, 
more suited to intermittent BG measurements, include the mean absolute difference (MAD), or mean 
of daily differences (MODD). Such metrics describe the average change in BG, or the difference in BG 
between days, but are limited in their ability to comprehensively describe the time course of variability 




Figure 6.3: Two sensor traces with similar Glucose Miles, but with very different mean BG. 
 
Time in band is another typical measure of variance good for combining and capturing level and 
variability, though it tends to be more of an implicit measurement, rather than explicit. It is a good 
aggregate measure for larger cohorts where central tendency makes time in band informative of overall 
cohort behaviour. Research has shown time in band, or time in range, can be associated with clinical 
outcomes [25, 26, 64, 65], in particular risk of microvascular complications [91]. 
 
However, whether the measurement is inside or outside of the band itself is discrete or binary. Thus, all 
variability or measures in the band are assumed to be clinically acceptable, and those outside are not. It 
may be a measure just inside the band is thus treated very different in analysis to one just outside, when 
both could be within measurement error. In addition, there is no agreement on appropriate bands, 
leading to difficulty in comparing the variability across studies [30]. By example, Figure 6.4 shows two 
sensor traces for a 4.4 mmol/L to 8.0 mmol/L range, which have the same time in band, but different, 




Figure 6.4: Two sensor traces with similar time in band, but differing clinical behaviour and 
impact. 
 
Other metrics for describing glycaemic variability exist, such as the mean amplitude of glucose 
excursions (MAGE), M-value, J-index, Low Blood Glucose Index (LBGI), High Blood Glucose Index 
(HBGI) and Average Daily Risk Range (ADRR) [75-78, 92]. Each of these metrics attempts to 
compensate for some aspect of the limitations of the metrics previously discussed, and specifically 
attempt to account for aspects of desirable glucose outcomes. Most of these metrics involves one or 
more aspects of the middle-range, time in band, or excursion size categories. All require some degree 
of correlation with outcomes to be clinically applicable, and have shown some degree of predictive 
capability [92]. While their disadvantages are presented elsewhere [75-78], the overall common 
disadvantage of such metrics is their calculation and interpretation is not transparent or intuitive to those 
unfamiliar with the metric, which may have impeded more widespread clinical uptake. 
 
Furthermore, most of these glycaemic variability metrics have been derived using point glucose 
measurements, and most have only been validated using these intermittent BG measurements to check 
the correlation with adverse outcomes. Only one of the metrics has been validated using CGM sensors, 
and was found to be correlated with increased hypoglycaemia given the measure of glycaemic 
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variability over some threshold [82]. However, more studies are needed for CGM sensor derived metrics 
and correlation with adverse outcomes. 
 
In addition to the various existing metrics for variability, variability in itself has been hard to define 
depending on what is clinically relevant. For example, observing the two sensor traces in Figure 6.1, on 
the timescale presented of 10 hours, the two sensor traces clearly have two differing levels of variability. 
CGM sensor trace 1 is far less variable than CGM sensor trace 2. However, stretching the timescale to 
a 24 hour period, the two sensor traces could be interpreted as having similar variability. Thus, there 
are currently no metrics that can adapt their timescales to account for the full time course information 
CGM sensors can provide. 
 
In summary, the large range of glucose metric definitions are confusing, contentious, and complicated. 
No metric adequately describes the time-course of glycaemia. Variability, in particular, is poorly 
captured by commonly used metrics, most of which are mathematically, rather than clinically, centred 
and defined. These limitations are particularly important in the context of emerging CGM technologies, 
which provide greater time resolution with greater, increasingly enhanced, point accuracy compared to 
intermittent measures [93, 115, 119, 238, 239]. CGMs thus offer the potential to significantly improve 
GC. However, to obtain this benefit, the best clinically defined metrics to capture patient glycaemic 
level and state must be established, which may require a new approach to defining variability. One that 
is clinically focused, rather than mathematically focused. 
 
6.3 CGM Technology 
CGM devices show significant as yet untapped potential for improving glycaemic monitoring and 
control, particularly due to their high measurement frequency. CGM sensors measure BG near 
continuously, with new generation devices able to measure at a rate of 1-6 times per minute [93-96], 
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and standard devices providing measurements every 5 minutes [97-100]. Compared to 1-6 hourly point-
of-care (POC) measurements in a well-staffed ICU [101], these devices offer huge potential to improve 
care and reduce workload in adult [174] and neonatal ICUs (NICU’s) [240]. 
 
The increased measurement frequency has many benefits for care, including the ability to monitor 
patient condition and, importantly, the trajectory of their glycaemia and condition in real time [167, 
196]. They also provide warning for hypoglycaemic events [87, 102], allowing early correction. Both 
benefits cannot be achieved with intermittent BG measures, where the minimum feasible regular 
measurement interval is ~1 hour, but clinical non-compliance can be high even at lesser rates [103-105], 
as seen in a recent study where protocolised measurement interval was 1 hour and the clinical 
measurement was closer to 3 hours [31, 39]. Even then, a patient’s condition may change significantly 
between hourly POC BG measures, resulting in hypoglycaemia remaining untreated for up to 50 
minutes. A CGM sensor, on the other hand, can alarm both at occurrence and predictively before it 
occurs. 
 
Despite these advantages, CGM sensors are not widely used in the ICU as CGM sensor technology still 
suffers limitations, including larger point error inaccuracies and sensor drift [107-114]. They are also 
expensive, so it may be hard to justify the cost versus potential benefits. The larger point accuracy errors 
over traditional intermittent BG measurement techniques have been well documented, with new CGM 
devices usually reporting gradually improving MARD values up to 8-12% [93, 115-117] as the 
technology has developed [93, 95, 98, 109, 115-125], compared to the 5% or lower common in 
intermittent POC measures [126]. Sensor drift is also still not widely recognised, even though it has 
shown to be a key driver of larger MARD and potential hypoglycaemia when used in GC [107, 127]. 
 
CGM technology also has the potential to reduce GC related workload in the ICU, providing more 
bedside data with lower blood sampling requirements [127-130]. Clinical practices have cited high 
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workload as a reason for reduced intermittent BG measures, as not every ICU has a low staff to patient 
ratio to justify the increased workload some GC protocols may require [68, 70, 71]. CGM sensors are 
able to give a continuous readout of the current BG measurement, and clinicians can adjust nutrition 
and insulin accordingly. However, this benefit has not yet reached regular care due to the limitations. 
 
Overall, CGM technology has not reached regular clinical use in ICU care, despite common acceptance 
in lower-risk outpatient type 1 diabetes care [159-163]. As CGM technology improves it will be able to 
replace intermittent measures used in the ICU today. However, with increased temporal measures and 
benefits to control, the same issues of how to quantify level and state remain. In fact, with the increased 
measurement rate of CGM technology, these issues are exacerbated as measures that work for 
intermittent measures may not be representative or accurate for use with CGMs. There thus remains a 
significant need for better, more clinically defined metrics, and in particular, those able to maximise the 
measurements delivered by CGMs. 
 
6.4 Vision for Glycaemic Control Metrics in the Future 
Given the development of increasingly accurate CGM devices, which offer higher resolution glycaemic 
monitoring, and the limitations of current measures of glycaemic level and variability, improved 
methods must be developed to describe glycaemia. Such methods will be important for effective 
research into cohort and patient specific behaviours and the benefits and harms of dysglycaemia and 
insulin therapy. These metrics should be clinically defined and thus associated with clinical outcomes, 
avoid reliance on statistical assumptions, easy to implement computationally in real-time, and simple 
to understand to aid uptake. 
 
Our vision for the future is a method for describing the time-course of glycaemic level and variability. 
Such a method would both improve reporting of glycaemic outcomes and better aid bedside glycaemic 
monitoring and treatment in patients.  The measure would be able to fully utilise the increased resolution 
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of modern CGM sensors allowing for analyses to relate the glycaemic states, and critically, any changes 
to these states, to clinical outcomes. The measure would be readily generalisable to other aspects of 
measurement and care, and would be easily compared across centres and cohorts under glycaemic 
control. 
 
6.5 Glycaemic State Analysis  
This section presents a novel method with the potential to fulfil the vision for the future defined. It 
develops a characterisation method for identifying Glycaemic States utilising CGM sensor data to 
monitor patient condition, both retrospectively, and in real-time. The algorithm builds on the idea of 
patient specificity, and also provides scope to adapt to changes in patient metabolism or clinical goals. 
The result is demonstrated on a cohort of 614 infants at risk for hypoglycaemia, and provides a first 
CGM-centric approach to simply quantifying Glycaemic State and variability in real-time. Infants were 
used for this analysis, as the data was conveniently available, and it was perfectly suited for the 
application being glucose dense CGM sensor data. It also had the additional benefit of being a study 
that explicitly looked for changes in glucose state around hypoglycaemia and normoglycaemia, and 
their relationship with outcomes. 
 
6.5.1 Using CGM Sensors to Understand the Evolution of Glycaemia over Time 
During the CHYLD study, the CHYLD researchers recognised qualitatively that the infants seemed to 
transition through distinctive Glycaemic States. These States, described by the clinicians as periods of 
relatively stable glucose levels over a period of 3-6 hours or longer, were patient specific, and seemed 
to vary not only from patient to patient, but also varied a lot within a patient. The research group thought 
there might be links between these Glycaemic States, and the neurodevelopmental outcomes of these 
infants presented in earlier studies [220, 221]. 
 
However, the research group had no way to quantify this variability or hypoglycaemia at the patient 
specific level, instead relying on visual inspection of the CGM sensor trace. Thus, this work set out to 
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design such an algorithmic tool to automatically quantify these Glycaemic States from these CGM 
sensor traces. This work would involve consultation with the clinicians in the CHYLD research group 
to establish what constitutes a State or State Change, and how these State Changes might be related to 
the clinical diagnoses of poor neurodevelopmental outcomes. 
 
In this chapter the ideas of lengths of a State and size of State Changes are explored, based on 
information gathered from clinicians to quantify behaviour that is of interest. The parameters are then 
set on clinician recommendations in order to use the algorithm on the CHYLD patient CGM sensor 
traces. Later in Chapter 7, these parameters are varied and tested against the associated 
neurodevelopmental outcomes to evaluate the effectiveness of this tool in aiding diagnosis. This chapter 
thus presents a first step towards a patient-specific description of state and variability. 
 
6.5.2 Calculating Patient States 
For each CGM trace, the mean of the whole CGM trace establishes a baseline average interstitial 
glucose (IG) level for that patient. The CGM data is then filtered using a centred 6-hour rolling average. 
Thus, there are 12x6-hour-average data points created using every hour of CGM data available (CGM 
sensor measurement frequency = 5 minutes), commencing 3 hours into the trace as the rolling average 
is calculated from the centre of the rolling window.  
 
The 6-hour rolling average is thus bootstrapped by taking the average of the first 3 hours of the CGM 
trace to begin the rolling average. The rolling average is then rolled forward by one measurement from 
this point for the next 3 hours until it reaches 6 hours. This method is reversed for the end of the CGM 
trace.  
Comparing the 6-hour rolling average to the arithmetic mean of the entire CGM trace yields a baseline 
variation around the overall mean value. These variations are examined for size to find state changes. 
Six hours is chosen because it filters out higher frequency glucose fluctuations, such as spikes just after 
feeding in the NICU, and allows for any true, long term changes in average IG, characterised as a State 
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Change in patient metabolic behaviour. 
 
Each time the 6-hour rolling average crosses the arithmetic average line, it is considered a possible State 
Change if specific clinically defined conditions are met: 
 
• More than 5 hours have passed since the last State Change, which assures “States” are 5 hours 
(or longer) periods of relatively constant average IG. 
• The State Glycaemic Average, defined as the average IG for a given State, was more than 0.3 
mmol/L higher or lower than the previous State Glycaemic Average, to reduce potential 
impacts of measurement error. 
 
If either condition is not met, the CGM data for the current arithmetic average crossing is combined 
with the CGM data of the previous State, and that State’s Glycaemic Average recalculated using the 
longer CGM data. This State characterisation process is shown in Figure 6.5. 
 
Importantly, while the 0.3 mmol/L threshold used here is based on clinical experience with neonates, it 
can be changed for any cohort or to find only larger changes. Similarly, a shorter or larger rolling 
average than 6-hours can be used, or they may be “nested” to find shorter State periods. Finally, State 
Changes per day (24 hours) are calculated to normalise results for comparison, but, equally, they could 





a) Clinical data for Patient 1. Black line shows the average for all of the CGM data. 
 
b) A centred rolling 6-hour average is calculated. Intersections between the rolling 6-hour average and IG 
average are noted by the red arrows. The rolling average is also bootstrapped to fill in the 3 hour gaps at the 
start and end of the rolling average line. 
 
c) The average for the Glycaemic States are calculated and plotted. 
Figure 6.5: Steps of the Glycaemic State characterisation process, showing how the rolling 
average and States are calculated. 
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The median [IQR] hours of CGM per patient are calculated, alongside the average change in sensor 
measured interstitial glucose (IG) after a State Change, the maximum State Change, the minimum State 
Change, number of State Changes that resulted in a higher IG (also as a percentage), and the number of 
State Changes that resulted in a lower IG (also as a percentage). The median IG average is also 
calculated, alongside the IQR and 90% range, to allow for comparison of this cohort to others. This is 
a search, given the method as defined by the CHYLD clinicians and statistician, for links between IG 
states and state changes, with outcomes. In particular, babies with more variable CGM traces were 
identified, qualitatively, by CHYLD researchers and clinicians as having poor outcomes. Thus, we are 
seeking to quantify that link. 
 
6.5.3 Case Study from a Neonatal Cohort 
6.5.3.1 Subjects and Continuous Glucose Monitoring 
The CHYLD Study recruited 614 infants born from 32 weeks gestation with one or more risk factors 
for neonatal hypoglycaemia, including the following: diabetic mother; preterm (<37 weeks); small 
(<10th centile or <2500 g); large (>90th centile or >4500 g); or acute illness [220]. The aim was to 
examine the relationship between the incidence and severity of neonatal hypoglycaemia in at-risk 
infants and neurodevelopmental outcome in childhood [220, 229]. A total of 481 infants had an 
interstitial CGMS System Gold CGM sensor (Medtronic Inc., Northridge, CA) inserted soon after birth 
in the lateral thigh, as previously described [229, 241]. Of these infants, 366 had more than 24 hours of 
CGM sensor data in the first 48 hours after birth, leading to 12356 total hours of CGM data (median 
[IQR]: 35.7 [30.5 38.4] hours/patient). Twelve further infants had more than 24 hours of CGM sensor 
data in the first 48 hours after birth, but had gaps in the data of more than 5 minutes (mean [IQR] = 8.1 
[3.0 8.9] hours) and were thus excluded from the analysis. The CGM sensor recorded a measurement 
every 5 minutes, but results were masked and did not influence clinical care. CGM data were 
downloaded and recalibrated to all blood glucose concentrations, measured on a blood gas analyser 




6.5.3.2 Results from a State and Variability Analysis 
Table 6.1 presents the overall results of the State analysis algorithm. The number of State Changes 
experienced by each infant was calculated, along with the number of State Changes/day, average 
absolute change in IG over a State Change, minimum and maximum overall State Changes over the 
entire cohort, and the number of State Changes with higher and lower IG. The results reported here give 
greater depth to glycaemia, highlighting the frequency of glycaemically stable or variable patients. 
 
Table 6.1: State Change analysis results. 
Patients 366 
Total hours 12356 
Hours/Patient (median) [IQR] 35.7 [30.5 38.4] 
Median IG Average [IQR], (90% range) (mmol/L) 3.7 [3.3 4.1], (3.0-5.0) 
Number patients with no State Changes 56 (15.3%) 
1 State Change 177 (48.4%) 
2 State Changes 81 (22.1%) 
3 State Changes 46 (12.6%) 
4 State Changes 5 (1.4%) 
5 State Changes 1 (0.3%) 
State Changes/day (median [IQR], (90% range)) 0.65 [0.54 1.16], (0-1.73) 
Median [IQR] absolute ΔIG State Change (mmol/L) 0.65 [0.45 0.92] 
Max State Change (mmol/L) 3.7 
Minimum State Change (mmol/L) 0.3 
Number of State Changes from lower to higher average IG 311 
Number of State Changes from higher to lower average IG 191 
 
Figure 6.6 presents case studies from the State characterisation process.  Figure 6.6(a) is a patient with 
3 separate States identified. The initial patient State is low IG and rising, shown by the State Average 
of ~3.5 mmol/L. At around 25 hours after birth, the patient enters a State of higher average IG, but also 
higher variability, as shown by the large fluctuations in the original CGM signal about the State Average 
of ~4.4 mmol/L. At 38 hours after birth, the patient enters a steep decline in IG. However, this decline 
is not reflected in the rolling 6-hour average as a State Change until 40 hours after birth, where the 
rolling average intersects the IG average line. This State is less variable than the previous State and also 
has an average closer to the total IG average, implying the patient becomes more stable. 
 
In Figure 6.6(b) only 2 States are identified, despite the CGM trace intersecting the IG average line 
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frequently. This is because the resulting States are less than the 0.3 mmol/L threshold required to reach 
a new Glycaemic State, and so these States are merged into one State. At approximately 33 hours, both 
the CGM trace and 6-hour rolling average decline enough, and for longer than the minimum 5 hour 
time frame, to describe a new, lower Glycaemic State. This patient has thus displayed a consistent and 
prolonged drop in glycaemia, which could be clinically significant. 
 
Figure 6.6(c) shows a patient with similar States and State Changes to Patient 2 in Figure 6.6(a). The 
patient starts at a lower State, experiences a State Change to a higher level, and then drops again to a 
State Average closer to the overall IG average. In this case, high variability results in the rolling average 
crossing the IG average more frequently, although subsequent changes would not be significant (<0.3 
mmol/L threshold). Clinically, it is of particular note that the IG spike at 37.4 hours after birth from 3.4 
mmol/L to 7.7 mmol/L occurs in 20 minutes of measurements in the absence of parenteral dextrose 
boluses or buccal dextrose gel, and is likely to be sensor error, rather than a rise in true IG [243], which 
the clinically defined approach discounts because the clinical definition of a State is far longer. In 
contrast, every other mathematically defined metric would be skewed by this error.  
 
Figure 6.6(d) shows a relatively stable patient with regard to State, similar to Patient 3 in Figure 6.6(b), 
but with higher variability around that State. If a threshold >0.3 mmol/L was used, the algorithm would 
identify only one State. Thus, the choice of threshold depends on the granularity desired in defining 
clinically significant States. It is possible to change the algorithm threshold to determine an optimum 







(a). State characterisation for Patient 2. 
 
(b). State characterisation for Patient 3. 
 
(c). State characterisation for Patient 4. 
 
(d). State characterisation for Patient 5. 
 
(e). State characterisation for Patient 6. 
 
(f). State characterisation for Patient 7. 
Figure 6.6: CGM data and Glycaemic State characterisation for Patients 2-7. 
 
Finally, Figure 6.6(e) shows the State characterisation for an infant characterised by the algorithm as 
having 2 States, with moderate variability of the CGM trace. At the start of the CGM trace, IG starts 
low and appears to be hypoglycaemic for around 2.5 hours, appearing to be at a single State of low 
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glucose concentrations. IG starts to rise back to normal levels at around 17 hours after birth. The 6-hour 
average crosses the IG average again at 43.5 hours, but does not exist long enough to define another 
State. Thus, only 2 States are characterised. However, different threshold choices or a change in 
beginning the moving average could capture such early potential States, if clinically relevant and 
desired, showing how the clinical definitions lead this algorithm and metric, thus better relating the 
metric and clinical goals. 
 
Only 1 patient recorded 5 State Changes in the 48 hour period, the maximum number for this cohort 
with the State definitions used. This variability could have been due to the infant being highly sensitive 
to feeding, where in the original data, the infant was fed at 4, 21.5, 36 and 42 hours, which roughly 
coincides with the large increases in IG. Figure 6.6(f) shows this patient, where it is clearer the IG 
average is abnormally high for this cohort. In particular, in the last portion of the CGM trace the infant 
is hyperglycaemic. 
 
6.5.3.3 Discussion of Case Study Results 
The majority of infants experienced less than 2 State Changes in the first 48 hours of birth (233 of 366 
patients, 64%), suggesting these patients at risk of hypoglycaemia remained in a relatively stable 
condition despite high rates of hypoglycaemia [229, 241]. There were more State Changes from a lower 
IG to a higher IG than the other way around. This bias may relate to fact the CHYLD cohort recruited 
infants at risk of hypoglycaemia. Equally, BG tends to rise in days after birth as the infant’s metabolism 
stabilises and their ability to take up nutrition and absorb it develops. 
 
Only ~25% of infants (96 out of 366) were parenterally fed. The majority were entirely enterally fed. 
Thus, these State Changes are most likely not due to changes in parenteral feed rate, an outcome negated 
by the clinical choices of how a State is defined in size and length of time. The States, defined by the 
0.3 mmol/L threshold chosen here, are by design larger than the expected rise due to a single enteral 
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feed. The 5-hour minimum State length is greater than a feed interval. Thus, it is unlikely that feeds 
would cause false State Changes as defined and used here, which again relates the metric definition to 
the specific clinical situation and goals for the cohort and is not possible with other current metrics.  
 
With respect to variability, it is captured first by State Changes per day, as discussed. It can also be 
further enhanced by examining area around the State level, a local AUC to compare or assess variability 
within a State. Similarly, a second level State analysis could be run with different clinical definitions to 
capture Sub-States. The method presented is thus clinically defined, as well as being very flexible in 
this regard. 
 
More adult CGM data is needed to compare to the infant results to see if there are any difference to 
level and variability between these two cohorts, or how much definitions of levels and States might 
need to vary between these cohorts. The method is generalisable enough to work with any CGM sensors 
and data, so using the method on other cohorts’ CGM data would yield valuable results to compare with 
this infant cohort or others. Equally, there is room to define the metric specific to clinical goals and 
cohorts, or even to compute multiple metrics simultaneously relevant to different clinical outcomes 
within a cohort. 
 
6.6 Discussion 
6.6.1 Comparison to Glycaemic Metrics 
The method of characterising States and State Changes offers some advantages over the mean and 
standard deviation, median and IQR, CoV, AUC, Glucose Miles and time in band metrics. This method 
for level and variability characterisation allows for increased resolution and descriptiveness in the 
reporting of individual and cohort glycaemia. In particular, stability to a particular ‘State’, and the 
variability around that State, are easily reported and intuitively interpreted. A particular strength of the 
method is in its ability to capture any changes, as critically ill patients can experience rapid changes in 




In comparison to mean and SD alone, or CoV, this method offers far greater insight to patient condition. 
As shown in Figure 6.2, two BG data sets can have the same mean and SD but very different glycaemic 
dynamics. A well-tuned state and variability analysis would distinguish between these States. 
Importantly, this method can distinguish between variability around a State, and variability between 
States, both of which have different time constants and thus may have different clinical implications. 
Similar outcomes hold regarding AUC and Glucose Miles.  
 
The metric used in this study is considered clinically relevant because it is clinically defined, where 
most prior metrics are defined mathematically, applied to clinical data, and then associated with a 
clinical outcome of interest to show its clinical relevance. In this case, the methods presented allow 
clinicians to derive the variability that is relevant for the issues/situation they are examining, while still 
assessing it in a uniform mathematical fashion. 
 
6.6.2 Potential Clinical Uses  
As noted, potential clinical uses are widespread. Foremost, is real-time use to allow visual inspection 
of changing glycaemia and variability around a State as it emerges and thus to track patient state. Such 
analysis could lead to better inputs to predictive models around patient outcomes [245-249]. 
 
Research uses are the likely first choice, where they would enable better analysis between and across 
studies. The simple calculations mean any data set could be calibrated to local clinical norms for 
comparison or to a standard set of definitions. In both cases, better comparison would lead to better 
understanding of the success and failure of GC interventions, thus enabling optimised care. 
 
6.6.3 Methodological Strengths and Limitations 
An important strength of the method is that all aspects are clinically defined. Thus, the parameters can 
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be changed in time or size to reflect the clinical behaviours to be captured. Hence, it is clinically defined 
and not dependent on any statistical distribution or assumptions. It can also be tuned to reflect clinical 
outcomes, where State thresholds may be adapted to reflect physiologically important changes in 
glycaemia.  
 
The method does have some disadvantages. Currently, the method has only been used with retrospective 
data, and its use in real time and on other neonatal or adult cohorts has not been thoroughly analysed. 
Real time processing and updated States can be achieved with filtering and bootstrapping methods, and 
expansions to other cohorts simply requires the application of the method to available data. The part of 
the method where the whole sensor trace average is calculated and set as a baseline would also need to 
change, as the whole sensor trace would not be available in real time. However, the method can change 
slightly to be based off a moving whole IG average that continually updates as more data is received 
from the sensor. Although this may have room for some erratic behaviour at the start of data collection, 
the IG average should stabilise as more and more data is collected. 
 
Another limitation of the method is that a new State can only be identified if the roiling average of the 
CGM sensor trace crosses the average glucose, IG. If, for example, a patient was highly variable in the 
short term above their IG, and then highly variable below their IG, only 2 States would be identified. 
This is partially affected by what the clinical parameters are set as for the method, for example setting 
shorter periods of interest can identify these shorter periods of variability, if that is what is of interest 
clinically. The variability within States can also be measured by combining with one of the metrics 
previously mentioned, such as Glucose Miles or AUC, if deemed appropriate for the analysis to be 
undertaken. 
 
The method has not been applied to a data set with clinical outcomes to distinguish what State durations 
or thresholds are clinically significant. This future work will validate the overall usefulness of this 
method, and its contribution to the vision of improved descriptors of Glycaemic State and variability. 
Future work would also look to improve the method by making it robust to gaps in sensor readings 
97 
 
using interpolation or other methods. 
 
Reported outcomes are still a simplification of the time-course of states and variability. While the State 
trace can easily and intuitively show changes in states and variability, attempts to reduce its properties 
to reported numbers in results or tables will inevitably result in some loss of information and intuitive 
interpretation of results. However, this issue is always going to be the limitation of any method to 
describe variability as a summary metric over any time period, and this method has the potential to 
allow greater description of glycaemic results in tabular or numerical form. For these results in 
particular, CGM sensor traces with length between 24 hours and 48 hours long have been pooled 
together in Table 6.1, which may hinder easy interpretation of these results. Thus, the data for the 




The vision, analysis and review presented has addressed an emerging and critical aspect of glycaemic 
control, the need for consensus summary metrics of glycaemic level or State and variability. Current 
metrics have significant limitations as most are not clinically defined, and thus poorly represent many 
aspects needed for a control metric. It thus presents and defines the problem, current state of the art, 
and presents a vision for the future of what is required, including a first research effort to meet the goals 
defined. The overall work includes an ongoing focus to relate the ideas and current state back to 
traditional control systems methods and engineering approaches. There is still significant room for 
innovation and new approaches, particularly as more and more data becomes available to engineers, 
and clinicians become increasingly willing to take on more novel approaches driven by rapid changes 
in technology and the ability to measure and control patients. These changes will only occur more 
rapidly, driven in major part by the increasingly poor economics of healthcare mixed with the need to 




Chapter 7 Variability and Level, and its Relationship with Clinical 
Outcomes 
7.1 Background  
As discussed in Chapter 6, normoglycaemia in infants is far less well studied than in adults. The 
literature thresholds are generally lower for both neonatal hyperglycaemia [222-226], and neonatal 
hypoglycaemia [220, 221, 250]. However, for neonatal hypoglycaemia in particular, agreement has not 
been reached by consensus on exactly what the thresholds are or what the treatments should be [220, 
228-230, 251], even though it is a common, but preventable cause of neonatal brain injury. 
 
Recent studies conducted by the CHYLD group have shown maintaining glucose concentration at or 
above 2.6 mmol/L may affect neurological function [221], while infants with higher or less stable blood 
glucose (BG) concentrations in the first 48 hours since birth had higher risk of neurosensory impairment 
[220]. While research has examined the effect of the level of hypoglycaemia on neurodevelopmental 
outcomes, it is still unclear what part/s the severity and duration of the dysglycaemia play in these 
outcomes. 
 
A further study by the CHYLD group sought to investigate factors influencing glycemic stability after 
neonatal hypoglycaemia and its relationship to neurodevelopmental outcomes [250]. It used many 
different metrics to quantify glycaemic stability and variability, including time to reach maximum 
interstitial glucose (IG) concentrations after dextrose boluses, and proportion of BG concentrations 
outside of a central band in the first 48 hours. The study showed that the risk of neurodevelopmental 
impairment was increased with both shorter and longer time to reach maximum IG after dextrose 
boluses, where the middle time to reach maximum IG was between 2.3-4.2 hours. Thus, slow or rapid 
recovery from hypoglycaemia appears to be associated with neurodevelopmental impairment. However, 
as discussed in Chapter 6, the metrics used to measure these outcomes can be lacking when trying to 




As Chapter 6 developed the State Characterisation method, after showing the need for such a metric for 
variability that takes full advantage of the time series of CGM sensors, the method needs to be validated. 
This validation may be possible through the association with neurodevelopmental outcomes previously 
used in the CHYLD study. If quantifying States can predict the outcomes with a high enough sensitivity 
and specificity, then the algorithm could be seen to accurately capture the patient dynamics and 
behaviour that is wanted while rejecting the rest of the noise that may confound the links between States 
and outcomes. 
 
This chapter utilises the State Change algorithm developed in Chapter 6 and [209], to more precisely 
quantify the glycaemic variability present in this infant cohort.  It applies the algorithm with varying 
parameters to characterise different clinically important glycaemic States, and examines the relationship 
between these State Changes and the infant cohorts’ neurodevelopmental outcomes. The algorithm is 
generalisable, so it can be adjusted to identify different clinically important behaviours in other cohorts. 
 
7.2 Methods 
The State Analysis method presented in Chapter 6 is used again to determine State Changes in an infant 
cohort. The infant cohort comes from the CHYLD Study in which the association of neonatal glycemia 
with neurodevelopmental outcomes at 4.5 years [221] and 2 years [220] were assessed. The CHYLD 
Study recruited 614 infants born from 32 weeks gestation with one or more risk factors for neonatal 
hypoglycaemia, including the following: diabetic mother; preterm (<37 weeks); small (<10th centile or 
<2500 g); large (>90th centile or >4500 g); or acute illness [220]. The aim was to examine the 
relationship between the incidence and severity of neonatal hypoglycaemia in at-risk infants and 




A total of 481 of these infants had an interstitial CGMS System Gold CGM sensor (Medtronic Inc., 
Northridge, CA) inserted soon after birth in the lateral thigh, as previously described [229, 241]. Of 
these infants, 366 had more than 24 hours of CGM sensor data in the first 48 hours after birth, leading 
to 12356 total hours of CGM data (median [IQR]: 35.7 [30.5 38.4] hours/patient). Twelve further infants 
had more than 24 hours of CGM sensor data in the first 48 hours after birth, but had gaps in the data of 
more than 5 minutes (mean [IQR] = 8.1 [3.0 8.9] hours) and were thus excluded from the analysis. The 
CGM sensor recorded a measurement every 5 minutes, but results were masked and did not influence 
clinical care. CGM data were downloaded and recalibrated to all BG concentrations, measured on a 
blood gas analyser [242]. 
 
This cohort is the same one used in the State Change analysis in Chapter 6. However, for the follow up 
neurodevelopmental assessments, a further 47 infants did not have data for either their 2 year or 4.5 
year assessments and so were excluded from further analysis. The resulting total number of infants in 
this analysis is thus 319. 
 
The State Change algorithm was run a total of 9 times, each time varying the clinical parameters of the 
algorithm to change the State Changes experienced by each infant. The two parameters varied were: 
• Hours allowed between State Changes, where 4 hours, 5 hours and 6 hours allowed were 
tested. This change tests State length. 
• The minimum difference between consecutive State Glycemic Averages, where minimum 
differences of 0.3, 0.4 and 0.5 mmol/L were tested. This change tests State magnitude in a 
clinically reasonable range. 
These test cases are summarised in Table 7.1. The range of 4-6 hours is based on clinical observations 
by the CHYLD study principle investigators. The State Change magnitude of 0.3-0.5 mmol/L is also 
based on their results. 
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Table 7.1: State Change algorithm parameter testing. 
Case Number Hours Allowed Between 
State Changes 
Minimum difference in 
State Glycaemic Averages 
(mmol/L) 
1 4 0.3 
2 4 0.4 
3 4 0.5 
4 5 0.3 
5 5 0.4 
6 5 0.5 
7 6 0.3 
8 6 0.4 
9 6 0.5 
 
After running the algorithm and determining the number of State Changes per day for each patient, this 
statistic was evaluated against the combined 2 year and 4.5 year neurodevelopmental outcome score. 
This score provides a simple yes if the infant had any neurodevelopmental problems at either 2 years 
old or 4.5 years old, or no if there were no problems at either stage. It is based on the combination of a 
range of clinically accepted scores, as used in [220, 221]. 
 
Receiver operator characteristic (ROC) curves where constructed to determine how well the metric of 
State Changes per Day was able to predict combined neurodevelopmental scores. State Changes per 
Day was calculated for each patient for standardisation as the hours of CGM recorded for each patient 
was different. 
 
To construct the ROC curve, the maximum State Changes per Day for a given case was divided by 10 
and rounded up to give the maximum number of steps in the ROC curve. The maximum number of 
State Changes per Day was then set as the condition for neurodevelopmental impairment, and the 
Sensitivity and Specificity values calculated accordingly. The State Changes per Day threshold for 
neurodevelopmental impairment was then incremented down in steps of 0.1, recalculating the 
Sensitivity and Specificity values at each stage, until the threshold was 0.0 State Changes per Day. The 
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ROC curve was then constructed from the Sensitivity and Specificity values, where each case had a 
separate ROC curve. 
 
7.3 Results 
Table 7.2 presents the results of the State Change algorithm running for the 9 test cases. The number 
and distribution of State Changes is shown alongside the cohort calculated State Changes per Day 
median and IQR. In general, results in Table 7.2 show as the hours allowed between State Changes is 
increased, less States are characterised, as expected. This outcome is also true as the minimum change 
in State Averages also increases. Increasing both parameters would cause less States to be characterised, 
so these outcomes make sense logically. 
 
Table 7.2: State Change algorithm parameter testing results. 
















1 42 144 76 50 6 1 0.73 [0.55 1.24] 
2 84 149 54 29 2 1 0.57 [0.50 1.06] 
3 120 134 49 15 1 0 0.54 [0.00 0.80] 
4 47 156 70 42 4 0 0.65 [0.54 1.16] 
5 88 154 50 27 0 0 0.57 [0.00 1.03] 
6 123 137 45 14 0 0 0.54 [0.00 0.71] 
7 58 162 70 27 2 0 0.61 [0.53 1.08] 
8 98 159 46 16 0 0 0.56 [0.00 0.77] 
9 137 138 36 8 0 0 0.53 [0.00 0.63] 
 
Figure 7.1(a)-(i) show the ROC curves for Cases 1 to 9. The predictive power of State Changes per Day 
does not appear to be a strong indicator for neurodevelopmental impairment, as seen by the closeness 





(a) Case 1 - ROC curve for the State Change algorithm run with 4 hours allowed between States, 
and a minimum 0.3 mmol/L difference in State Averages. 
 
(b) Case 2 - ROC curve for the State Change algorithm run with 4 hours allowed between States, 
and a minimum 0.4 mmol/L difference in State Averages. 
 
(c) Case 3 - ROC curve for the State Change algorithm run with 4 hours allowed between States, 







(d) Case 4 - ROC curve for the State Change algorithm run with 5 hours allowed between States, 
and a minimum 0.3 mmol/L difference in State Averages. 
 
(e) Case 5 - ROC curve for the State Change algorithm run with 5 hours allowed between States, 
and a minimum 0.4 mmol/L difference in State Averages. 
 
(f) Case 6 - ROC curve for the State Change algorithm run with 5 hours allowed between States, 






(g) Case 7 - ROC curve for the State Change algorithm run with 6 hours allowed between States, 
and a minimum 0.3 mmol/L difference in State Averages. 
 
(h) Case 8 - ROC curve for the State Change algorithm run with 6 hours allowed between States, 
and a minimum 0.4 mmol/L difference in State Averages. 
 
(i) Case 9 - ROC curve for the State Change algorithm run with 6 hours allowed between States, 
and a minimum 0.5 mmol/L difference in State Averages. 





Although analysing State Change per Day, and thus glycaemic variability, against neurodevelopmental 
impairment did not seem to give any conclusive results,  it is clear from Burakevych et al. [250] there 
is some relationship between the glycaemic response to hypoglycaemia, and impairment. The CHYLD 
Study found slow or rapid recovery of hypoglycaemia was associated with neurosensory impairment. 
From the State Change analysis, the rapid recovery from hypoglycaemia would appear as a quick State 
Change, after which could be multiple State Changes if the infant is unable to control their BG levels, 
or few if they were then stable. In relation to the ROC curves, this outcome would cover the maximum 
State Changes per Day condition used to predict neurodevelopmental impairment. However, rate of 
change was not considered here, but could be captured by a shorter average time. 
 
For the slow recovery of hypoglycaemia, the other situational response, this outcome would appear as 
a long, continuous State. Being glycaemically stable at normal BG levels would usually be considered 
positive, but to slowly recover and increase BG levels to normal from hypoglycaemia, even after a 
dextrose bolus, would imply the infant is also struggling to control their BG level, which would be 
considered detrimental. However, in the case of the State Change analysis and the ROC curves, this 
outcome would appear as the opposite condition to predict neurodevelopmental impairment, thus giving 
false negatives and lowering the prediction power, as seen in the plots. There is thus a need to potentially 




A glycaemic State Change algorithm was applied to an infant cohort to assess glycaemic variability in 
the first 48 hours since birth. The algorithm was run with differing parameters to capture different levels 
of clinically important behaviours, and to test for what values were clinically important in this cohort. 
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ROC curves were formed from each case of parameter testing, using State Changes per Day as the main 
measurement of glycaemic variability. The max amount of State Changes per Day in any given case 
was used as the condition for neurodevelopmental impairment in this cohort. The ROC curve analysis 
was inconclusive, possibly due to the mixed behaviour of recovery from hypoglycaemia that was found 
to be associated with neurodevelopmental impairment, where a slow or rapid recovery was more 
detrimental. This slow or rapid recovery from hypoglycaemia would appear as both the minimum and 
maximum State Changes per Day respectively, and thus multivariate ROC curve analysis may need to 




Chapter 8 Conclusions 
BG dysregulation in a critically ill cohort is associated with increased complications leading to 
increased morbidity and mortality. Safe and effective external glycaemic control methods have been 
shown to improve outcomes in this cohort. Such GC protocols include the STAR protocol, currently in 
use at the Christchurch Hospital ICU in New Zealand. However, achieving safe and effective control 
consistently, to all patients, has been challenging for most GC methods and protocols. Two major 
barriers to achieving this consistency are BG measurement frequency and glycaemic variability. 
 
One of the ways BG measurement frequency can be enhanced, without drastically increasing workload, 
is utilising CGM sensors, which can measure up to 4 times per minute, rather than intermittent 
measurements, where measurement periods are usually every 1-6 hours, to guide GC protocols. 
However, using CGM sensors over intermittent measures usually comes with a trade-off of sensor 
measurement accuracy, which, depending on the severity of the error at a given time, may be detrimental 
to control. Thus, there is a need to model and characterise these errors, so that CGM sensors can be 
modelled in-silico to assess the potential trade-offs between safety, performance and workload in GC. 
 
In this work, a CGM sensor was characterised from patient clinical data using an auto-regressive 
modelling approach. The method presented in this work has the benefits of explicitly accounting for 
sensor drift and requiring far fewer independently sampled blood glucose measures than other methods. 
Sensor traces can be simulated for BG taken at a clinically realistic rate to create the model. Sensor 
simulations showed modelled sensor behaviour was very similar to the original clinical data, with very 
high similarity in MARD, and equally similar Bland-Altman and Clark Error Grid results further 
validating the model. The novel use of the Trend Compass to validate the trend accuracy reproduction 
within simulation further showed that the model method is able to accurately capture both point 
accuracy and trend accuracy. The overall model method is general to any similar sensor and readily 
extended to interstitial sensors, with or without including interstitial glucose dynamics. It is easily 
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simulated on typical clinical data and thus readily able to be incorporated into proven virtual patients to 
optimise protocol designs to utilise CGMs in the intensive care unit for glycaemic control. 
 
The model of the CGM sensor was then used in place of intermittent BG measurements to guide GC 
decisions under the STAR protocol in a virtual environment. Virtual trials are used to evaluate the 
impact on safety, performance, and workload of implementing these or similar CGM sensors for GC 
using the STAR protocol. Using a range of guard rails and/or rolling windows delineated trade-offs 
found in using CGM sensors, and decreased the number of required blood draws for BG measures by 
up to 73%, while also maintaining GC performance and patient safety. Performance and safety were 
robust to reasonable changes in sensor recalibration period, as well as to changes in rolling window 
parameters of window length and BG change. Overall, the use of a typical CGM sensor in clinically 
validated virtual trials shows the potential to reduce clinical workload significantly. The lack of equally 
significant improvements in performance are likely due to the already very good and clinically proven 
performance of the STAR GC protocol employed. 
 
Using these characterisation and simulation techniques, this work has shown using CGM sensor 
technology may improve some aspects of GC, and help the field move towards a future where GC is 
much more automated. Benefits and areas of improvement can be revealed in a safe in-silico 
environment, where protocols and treatment parameters can be optimised before transitioning the 
technology to a real critical care unit. 
 
A further barrier to achieving safe, effective and consistent glycaemic control includes glycaemic 
variability. Glycaemic variability has been shown to also result in worse outcomes, and so the effective 
evaluation and control of any variability would help to improve these outcomes. However, current 
metrics used to identify glycaemic variability are lacking, and do not take advantage of the full time 
course of data that new CGM sensors can provide. 
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In this work, the currently used metrics of glycaemic level or State and variability are summarised. 
Current metrics have significant limitations as most are not clinically defined, and thus poorly represent 
many aspects needed for a control metric. It thus presents and defines the problem, current state of the 
art, and presents a vision for the future of what is required, including a first research effort to meet the 
goals defined. The metric developed uses the full time series data of CGM sensors to characterise 
different glycaemic states that are clinically important, so that variability can be seen visually. 
 
The overall work includes an ongoing focus to relate the ideas and current state back to traditional 
control systems methods and engineering approaches. There is still significant room for innovation and 
new approaches, particularly as more and more data becomes available to engineers, and clinicians 
become increasingly willing to take on more novel approaches driven by rapid changes in technology 
and the ability to measure and control patients. These changes will only occur more rapidly, driven in 
major part by the increasingly poor economics of healthcare mixed with the need to keep care more 




Chapter 9 Future Work 
A model for a continuous glucose monitoring sensor was developed to characterise the errors of the 
Glysure CGM device. The CGM sensor model was implemented in in-silico virtual trials. A new metric 
to measure glycaemic variability, taking advantage of increased frequency of CGM sensor 
measurements, was also developed and applied to an infant cohort. Initial results have shown that 
improvements in workload may be possible, whilst maintaining safety and performance of GC, and that 
the algorithm can be applied successfully to identify patient glycaemic states. Further avenues of 
research have been opened up that may build on the work. 
 
9.1 Characterisation of other CGM Sensors for In-silico Testing  
So far, this research has only characterised the sensor error of one type of CGM sensor. The 
characterisation method is generalisable to any CGM sensor, and thus could be used on other data sets 
to characterise and simulate other sensors in a virtual GC environment, to evaluate the best type of 
sensor to use for GC.  
 
This is especially important considering the vast number of CGM sensors that are available, many of 
which utilise different glucose sensing technologies, and also have different insertion sites on the body. 
Virtual trials could be run, and comparisons made to cheaply and efficiently evaluate the best CGM 
sensor to use for GC in terms of cost, performance, safety and workload. 
 
9.2 Validation of the State Characterisation Method using Short Term Clinical Outcomes 
Before further research is done on relating the State Characterisation Method on long term outcomes 
such as the neurodevelopmental outcomes in later life in [220, 221], the method needs to be validated 
more on immediate outcomes in the NICU or ICU. Often, additional data describing patient state is 
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collected at the time of NICU or ICU admission. These shorter-term diagnoses might be more readily 
linked to characterised State Changes. 
 
Additionally, States could be characterised for patients undergoing GC. Theoretically, as GC 
progresses, the patient state should be converging towards a stable state in some specified glycaemic 
band. This characterisation could potentially be done across a cohort of patients undergoing GC guided 
by CGM sensor measurements. Collecting additional data such as APACHE scores in the adult ICU 
may also yield more diagnoses to link State Changes to. 
 
9.3 Further Analysis into the Relationship between Glycaemic States and 
Neurodevelopmental Outcomes  
More research has been carried out analysing the relationship between glycaemic variability during 
recovery from hypoglycaemia in an infant cohort that has shown that both slow and rapid recovery from 
hypoglycaemia may be associated with negative outcomes. The State Change algorithm was able to 
successfully quantify Glycaemic States and variability in this cohort using different clinical parameters 
for State Changes. However, the work was unable to show any association with neurodevelopmental 
outcomes using single variable analysis and ROC curves, where the main condition for 
neurodevelopmental impairment was an excessive amount of State Changes per Day. 
 
Analysis of the State Changes per Day metric using multi-variable analysis, or improving the ROC 
curve sensitivity and specificity values by evaluating better conditions for neurodevelopmental 




9.4 Particle Filters to Improve CGM Sensor Measurement and Accuracy 
Utilising CGM sensor measurements to guide GC in an in-silico environment have shown promise in 
reducing workload, while maintaining safety and performance of GC. However, even with frequent 
recalibrations, CGM sensors are known to have much higher measurement error than intermittent 
measures. 
 
To further increase the safety and performance of a GC protocol utilising CGM sensors, a particle filter 
could be built and tested on in-silico patients. The particle filter would utilise both measurements from 
the CGM sensor, as well as intermittent measurements from mandatory actions such as recalibrations, 
to better track blood glucose. The particle filter would be able to combine the accuracy of intermittent 
measurements with the continuous readings from the CGM sensor to give a more accurate reading of 
BG than just CGM sensor measurement alone, while also providing the early warning system of any 
drastic change in BG. 
 
A particle filter would be a better choice of filter over others, such as the Kalman filter, for a few 
reasons. The particle filter is much more robust to sensor error, can deal with non-Gaussian noise, and 
can also be used on non-linear models such as the ICING model. Thus, if any filter were to be 
computationally added to increase the accuracy of the simulated sensor, the recommendation would be 
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